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Abstract
In this thesis, we are concerned with optimal control problems related to one of the major
global health problems facing human beings, diabetes, with a staggering 4.9 million deaths
attributed to it in 2014. Diabetes is an incurable disease caused when the pancreas no
longer makes insulin (in the case of type 1 diabetes), or when the pancreas cannot make
enough insulin and/or the body develops insulin resistance (in the case of type 2 diabetes).
The ultimate aim of this thesis is to propose and illustrate a general methodology for the
analysis and control of the human blood glucose regulatory system.
We adopt a comprehensive dynamic model of the blood glucose regulatory system and
show how it can be readily tted to individuals. This is done by formulating an optimal
parameter selection problem in which optimal values for the model parameters must be
selected so that the resulting model best ts the desired data. Then, a numerical solution
procedure for this optimal parameter selection problem using the optimal control software
MISER3.3 is proposed. We also investigate the sensitivity of the resulting optimized model
with respect to the insulin release rate, which is the body's natural feedback control.
Moreover, we demonstrate how optimal open loop controls can be readily calculated for
this model.
We then extend the model to include bolus insulin injections for the treatment of
diabetic patients. We also show how to incorporate the role of exercise into this model.
We formulate the combined model as an optimal control problem in which the aim is
to determine optimal injection times, optimal injection volumes and optimal exercise
regimes to regulate the blood glucose level. A numerical approach, based on control
parameterization and a time scaling transformation, is then developed for solving the
optimal control problem. Numerical results for dierent scenarios involving type 1 and
type 2 diabetes show that optimal treatment regimes can be readily determined via the
proposed approach. The optimal regimes are successful at regulating the blood glucose
level.
In future work, improvements can be made to incorporate other important treatment
regimes, particularly for type 2 diabetics, into the model.
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CHAPTER 1
Introduction
1.1 Blood glucose regulatory system
In this thesis, we are concerned with optimal control problems related to human health.
One of the major global health problems is diabetes with a staggering 4.9 million deaths
attributed to it in 2014 [2]. Figures about diabetes released by the International Diabetes
Federation (IDF) show that 387 million people worldwide have diabetes. The Western
Pacic region, which includes highly developed countries such as Australia and Japan,
and fast growing economies such as China, accounts for 138 million diabetes suerers [2].
Correct blood glucose levels are crucial to maintaining health. The normal concentra-
tion of blood glucose in a healthy person is between 80 to 120 mg/dl (4.4 to 6.7 mmol/l).
Concentrations outside of this range cause either hyperglycemia (above 120 mg/dl) or
hypoglycemia (under 80 mg/dl). Prolonged irregularities in the blood glucose level result
in major health problems.
Diabetes is an incurable disease caused when the pancreas no longer makes insulin (in
the case of type 1 diabetes), or when the pancreas cannot make enough insulin and/or the
body develops insulin resistance (in the case of type 2 diabetes). Some common signs and
symptoms of diabetes are increased thirst, frequent urination, extreme hunger, fatigue,
blurred vision, slow-healing sores and the presence of ketones in the urine (ketones are
the byproducts of broken down fatty acids in the body that increase due to weight loss or
when there is not enough insulin available). Left unmanaged, diabetes has harmful eects
on the vascular system due to the resulting high blood glucose levels [19]. Macrovascular
complications are driven by atherosclerosis (the formation of brofatty plaque on artery
walls) which leads to the narrowing of arterial walls throughout the body and can result
in strokes or cardiac arrest. Microvascular complications are due to damage to very small
blood vessels and nerves. Diabetic retinopathy results from damage to the tiny blood
vessels at the back of the eye and can seriously aect vision to the point of blindness.
Diabetic nephropathy is a similar process occurring in the kidneys which reduces their
ability to lter blood properly and may lead to complete kidney failure. Finally, diabetic
1
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neuropathy is the dysfunction of peripheral nerves which results in the inability to feel pain
in the extremities of the body, particularly in the hands and feet. This frequently results in
undetected injuries which do not heal well and may require amputations. Hypoglycemia,
on the other hand, causes serious short term impacts such as fainting, brain failure and
death. In addition to type 1 and type 2 diabetes, there are other forms of diabetes such
as gestational diabetes which may occur during pregnancy and often disappears after the
birth of the child.
Before going deeper into the blood glucose regulatory system, it is worth giving a
description of the main components. Glucose is the simplest form of sugar and represents
the primary source of energy for cells in the human body. Glycogen has a modied
molecular structure compared to glucose and is generated for the purpose of storing energy
in the body. Insulin is a natural hormone made by the pancreas which regulates the
blood glucose level. Cells cannot absorb glucose directly from the bloodstream without
insulin. Glucagon, a natural hormone made by alpha cells in the pancreas, promotes the
glycogenolysis process (the breakdown of glycogen to glucose) in the liver.
In a healthy person, stabilization of the blood glucose level in the normal range is
achieved in multiple ways. The hormones insulin, which is produced by  cells, and
glucagon, which is produced by  cells, are the most important regulators of the blood
glucose level. They are both secreted by the endocrine pancreas and stabilize the glucose
level in the blood via natural feedback loops. When the glucose concentration rises too
high, insulin is secreted which encourages glucose uptake by cells as well as conversion of
glucose to glycogen, there by lowering the blood glucose concentration. In the opposite
manner, a decrease in blood glucose below the desired level stimulates glucagon secretion
which in turn increases the glucose concentration towards normal through the conversion
of glycogen to glucose. Factors aecting the blood glucose concentration can be divided
into ve categories:
(i) Food intake. This includes the timing of meals, composition of the food and quantity.
(ii) Medication used in the case of a diabetic subject. This includes insulin and other
drugs which stimulate insulin production or reduce insulin resistance in the body.
(iii) The level of exercise of an individual.
(iv) Biological factors such as stress or illness.
(v) Environmental factors such as climate and altitude.
For diabetic patients in particular, additional factors can have a signicant impact on
blood glucose levels:
(i) The type of insulin preparation used (short or long acting).
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Types of insulin Action Example
fast or rapid-acting insulin onset within 15 mins. after
injection, reaches peak be-
tween 30 to 90 mins. and
lasts for 3 to 5 hrs.
insulin aspart and insulin
lispro
short-acting insulin onset within 30 to 60 mins.
after injection, reaches peak
between 2 to 4 hrs. and
lasts for 5 to 8 hrs.
regular
intermediate-acting insulin onset within 1 to 3 hrs. af-
ter injection, reaches peak
after 8 hrs. and lasts for 12
to 16 hrs.
NPH
long-acting insulin onset within 1 hour of injec-
tion, is peak-less and lasts
for 20 to 26 hrs (1 or 2 injec-
tions last for a whole day)
insulin glargine
mixed insulin Is a combination of ei-
ther rapid-acting or short
acting insulin with an
intermediate-acting insulin,
onset within 10 to 15 mins,
its peak varies and lasts for
10 to 16 hrs.
75% insulin lispro pro-
tamine and 25% insulin
lispro, 70% insulin aspart
protamine and 30% insulin
aspart, or regular with
NPH
Table 1.1: Insulin types and their characteristics (onset, peak times and duration)
(ii) The injection site and delivery type (bolus or continuous infusion).
(iii) The patient's characteristics.
Since physical characteristics vary from person to person, dierent patients usually have
somewhat dierent responses to the same treatment. Even responses of the same patient
to the same treatment can vary under dierent circumstances.
For each type of insulin, there is an onset time (i.e. when the insulin starts to work
after it is taken), a peak time (i.e. when the maximum eect of insulin is observed) and a
duration (i.e. the time during which the insulin continues to work). These characteristics
vary amongst insulin types and they may also dier from patient to patient. Table 1.1
gives a brief overview of insulin types and their estimated characteristics (onset, peak
times and duration).
To survive type 1 diabetes, a lifetime of exogenous insulin injections and regular mon-
itoring of blood glucose concentration is required. On the other hand, type 2 diabetics
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Figure 1.1: Closed loop system
require insulin only when diet restrictions, increased physical activity and non insulin
medications are insucient to control blood glucose levels. Therefore, the problem of
closed loop blood glucose level regulation via insulin infusion has been the subject of
investigations for decades, with studies conducted in both an empirical framework and a
mathematical one. While the empirical framework involves clinical experience and knowl-
edge, the mathematical framework uses mathematical models (which describe the intrinsic
glucose regulation performed by the endocrine pancreas) to formulate appropriate schemes
for regulation of the blood glucose level.
The formulation of a control rule is based on the knowledge we have about components
of the closed loop system which is often referred to as an articial pancreas (see Figure
1.1). Thus, the ultimate aim of a control algorithm is to mimic the functionality of the
pancreas . While these control algorithms are usually closed loop in practice, their design
can be enhanced signicantly by comparison to corresponding open loop optimal controls.
One aim of this thesis is to construct open loop optimal controls for diabetic patients.
Mathematically based control methods rely on dynamical models of the body's blood
glucose regulatory system. To date, several nonlinear mathematical models for the blood
glucose regulatory system have been proposed. These range from simple ones such as
the Bergman minimal model [10], which has been widely cited, to more comprehensive
ones [13]. Comprehensive models aim to integrate knowledge about the blood glucose reg-
ulation system into a large nonlinear compartmental model involving a variety of param-
eters and factors that inuence the system. Several control models, such as proportional-
integral-derivative (PID) control [38], robust servo control [28], and model predictive
control (MPC) [23], have been developed based on the Bergman minimal model. In most
of the existing control models, the glucose regulatory system is greatly simplied and
only glucose and insulin are considered. We will discuss a variety of dynamic and control
models in more detail in the next chapter of this thesis.
The aim of this thesis is to propose and illustrate a general methodology for the analysis
and control of the human blood glucose regulatory system. We adopt a comprehensive
dynamic model of intermediate complexity and show how it can be readily tted to
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individuals. We also demonstrate how optimal open loop controls can be calculated for
this model. We then extend the model to include bolus insulin injections for the treatment
of diabetic patients. We also show how to incorporate the role of exercise into this model
and determine combined optimal insulin delivery and exercise regimes. Finally, we point
out other important treatment regimes that should also be incorporated into the model
in the future.
1.2 Optimal control
Optimal control and optimal parameter selection problems arise in many elds such as -
nancial management, forestry, agriculture, defense, civil, chemical, electrical and mechan-
ical engineering, biology and the social sciences. Broadly speaking, an optimal control
problem seeks to optimize a performance index subject to a set of dynamic and, possi-
bly, algebraic constraints. The dynamic constraints may consist of a set of dierentiable
equations (ordinary or partial) or a set of dierence equations. These equations may
be deterministic or stochastic in nature. In this thesis, we formulate and solve several
practical problems related to the insulin-glucose dynamics in the human body. These
formulations are in the form of optimal parameter selection problems as well as combined
optimal parameter selection and optimal control problems involving systems of ordinary
dierential equations. We give a general formulation of these problems and discuss their
solution methods in this and the following sections.
A general formulation of a basic optimal control problem can be described as follows.
Consider the dynamical system
_x(t) = f(t; x(t); u(t)); (1.1)
over the time horizon t 2 [0; T ] and the initial condition
x(0) = x0; (1.2)
where
 x(t) 2 Rn is the state vector at time t;
 u(t) 2 Rr is the control vector (whose components are the control variables) at time
t;
 f : RRnRr ! Rn is a given function, assumed to be continuously dierentiable
with respect to x and u, and piecewise continuous with respect to time t;
 T is the terminal time;
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 x0 2 Rn is a given initial state vector;
 n is the number of states; and
 r is the number of controls.
A function u : [0; T ]! Rr represents a control strategy for system (1.1)-(1.2) and returns
the value of the control vector at each point in the time horizon. Such a control strategy
is called a control function and it is usually bounded. Hence, we normally assume that
the range of the control function is contained within some proper subset U = fu =
[u1; : : : ; ur]
T : i  ui  i; i = 1; : : : ; rg  Rr , which is called the control restraint set.
Here, i and i are given constants such that i < i for each i = 1; : : : ; r. A bounded
measurable function u : [0; T ] ! U such that u(t) 2 U for all t 2 [0; T ] is called an
admissible control. Let U be the class of all such admissible controls.
The control function inuences the state through the dynamic system (1.1). In other
words, the control changes its value during the time interval [0; T ] which, in turn, aects
the evolution of the state x(t) according to the dynamic system (1.1) and (1.2). Let x(ju)
denote the solution of (1.1) and (1.2) corresponding to u 2 U .
Many practical problems include a variety of dierent constraints imposed on the state
and control. A canonical form for system constraints can be mathematically expressed
as:
Gi(u) = i(x(T )) +
Z T
0
Li(t; x(t); u(t))dt
8<:= 0; i = 1; : : : ; qe; 0; i = qe + 1; : : : ; q; (1.3)
where q is the total number of canonical constraints and qe is the number of canonical
equality constraints. In an optimal control problem, we seek to optimize a cost functional
of the form
G0(u) = 0(x(T )) +
Z T
0
L0(t; x(t); u(t))dt: (1.4)
Here, i and Li; i = 0; 1; : : : ; q; are given continuously dierentiable functions with respect
to all their arguments. Thus, we state the general formulation of an optimal control
problem as choosing a control u 2 U so as to minimize the objective (1.4) subject to the
dynamics (1.1) and (1.2) and subject to the constraints (1.3). Let this be denoted as
Problem P1. Analytical solutions of Problem P1 are only possible for simple cases. These
normally require the rst order necessary conditions of optimality (the Euler-Lagrange
equations in the case of unconstrained problems or the Pontryagin Minimum Principle in
the case of control bounds) or solutions of the Hamilton-Jacobi-Bellman (HJB) equation
derived via the dynamical programming principle.
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1.3 Numerical solution techniques
In general, it is dicult to solve optimal control problems analytically. Thus, numerical
methods are required. Numerical methods are classied into two broad categories: direct
and indirect methods. A thorough review for these methods and their various approaches
is given in [48]. Essentially, in an indirect method, the rst order optimality conditions
are applied to the original problem, resulting in a two point boundary value problem
(TPBVP). This can then be solved numerically with either shooting methods or multiple
shooting methods. On the other hand, in direct methods, the control and/or the state
of the optimal control problem are approximated via a discretization process. This leads
to a discretized version of the problem which can then be regarded as a mathematical
programming problem and solved numerically using a variety of techniques. When only
the control is approximated, the direct method is referred to as a control parameterization
method. When both the state and the control are discretized, the approach is known as
a state discretization method. As the control parameterization approach will be adopted
in this thesis, we give a more detailed review below.
1.3.1 Control parameterization
Control parameterization is one of the common techniques to solve optimal control prob-
lems numerically [55]. Let us consider its application to Problem P1. The basic concept
of this technique centers around two steps; partition the time horizon of a problem into
a number of xed subintervals, i.e. partition the time horizon [0; T ] into a set of points
P = ff0; 1; : : : ; Ng; 0 = 0; N = T; j 1 < j; j = 1; : : : ; Ng, where N is the number of
intervals in the partition chosen by the user. We then approximate each control function
ui(t); i = 1; : : : ; r; by a combination of basis functions  j; j = 1; : : : ; N; as follows:
ui(t) =
NX
j=1
ij j(t); j = 1; : : : ; N; i = 1; : : : ; r; (1.5)
where ij; i = 1; : : : ; r; j = 1; : : : ; N; are decision variables which need to be optimally
chosen in order to minimize the objective function. Most applications of control param-
eterization are implemented with piecewise constant basis functions. However, the basis
functions can take other forms such quadratic or cubic or non polynomial [25]. In the
case of piecewise constant basis functions, we choose  j(t) = [j 1;j); where
[j 1;j)(t) =
8<:1; if t 2 [j 1; j);0; otherwise; (1.6)
is the indicator function with respect to the interval [j 1; j). The approximate control
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function can then be written as:
ui(t) =
NX
j=1
ij[j 1;j)(t); (1.7)
where i  ij  j; i = 1; : : : ; r; j = 1; : : : ; N: Let i = [i1; i2; : : : ; iN ]; i = 1; : : : ; r;
and  = [T1 ; 
T
2 ; : : : ; 
T
r ]
T . Furthermore, let x(j) denote the solution of (1.1) and (1.2)
when the control is dened by (1.7). Then, the approximate problem resulting from
control parameterization can be written as follows. Minimize
GN0 () = 0(x(T j)) +
Z T
0
~L0(t; x(tj); )dt (1.8)
subject to dynamical system,
_x(t) = ~f(t; x(t); ); t 2 [i 1; i); i = 1; : : : ; N; (1.9)
the initial condition (1.2) and the canonical constraints
GNi () = i(x(T j)) +
Z T
0
~Li(t; x(tj); )dt
8<:= 0; i = 1; : : : ; qe; 0; i = qe + 1; : : : ; q; (1.10)
where ~f(t; x(t); ) and ~Li(t; x(tj); ); i = 0; : : : ; q; denote the functions f and Li; i =
0; : : : ; q, respectively, with the argument u(t) replaced by the form (1.7). The resulting
approximate problem, referred to as Problem P2, is essentially a mathematical program-
ming problem which depends on a nite number of decision variables. Once the gradients
of this problem have been calculated via the formulation of Hamiltonian functions and the
solution of costate dynamics [55], it can be solved numerically by using a gradient based
optimization method like sequential quadratic programming (SQP) (see [35], [14], [43]
and [51]). The optimal control software MISER3.3 [25] implements this approach.
1.3.2 MISER
The FORTRAN based optimal control software MISER was originally developed by K.L.
Teo and C.J. Goh in 1988 [21]. This version of MISER essentially solves the Problem
P2 described in the last section. A much more comprehensive and user friendly version,
MISER3, was created by L.S. Jennings in 1991 [24]. In 2004, the latest version of MISER
(MISER3.3) was developed. It incorporated signicant improvements such as allowing
state jumps in the dynamic system and multiple characteristic times in the objective
and constraints [25]. Thus, MISER3.3 has become a powerful software which can be
used to solve a wide range of practical optimal control problems. As mentioned above,
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MISER's theoretical basis is the control parameterization technique. It basically deals
with three standard forms of constraints: canonical constraints of the form given above,
continuous inequality constraints on the states and linear constraints involving only the
controls. Users only require a basic knowledge of multi-variable calculus and elementary
FORTRAN programming skills to solve problems with features allowed by MISER3.3.
More complex problems that do not t the standard framework of MISER3.3 can often
be transformed into an equivalent standard form suitable for the software.
1.3.3 Additional features allowed in MISER3.3
MISER3.3 generates a numerical solution to the general continuous optimal control and
optimal parameter selection problem in the form stated below. Here (u; z) 2 UZ, where
u(t) 2 U is the control function as dened previously, and z 2 Z is a vector of system
parameters, where Z=fz = [z1; : : : ; zm]T : ai  zi  bi; i = 1; : : : ;mg is a set of feasible
system parameters. The problem is to choose (u; z) 2 U  Z to minimize
G0(u; z) =
MX
j=1
0;j(x(j); z) +
Z T
0
L0(t; x(t); u(t); z)dt (1.11)
subject to the dynamic system,
_x(t) = f(t; x(t); u(t); z); t 2 [0; T ]; (1.12)
the initial conditions
x(0) = x0(z); (1.13)
the canonical constraints
Gi(u; z) =
MX
j=1
i;j(x(j); z) +
Z j
0
Li(t; x(t); u(t); z)dt
8<:= 0; i = 1; : : : ; qe; 0; i = qe + 1; : : : ; q; (1.14)
and the continuous inequality constraints
hi(x(t); z)  0; t 2 [0; T ]; i = 1; : : : ; nc; (1.15)
where
 f; Li and i;j are given functions, assumed to be continuously dierentiable with
respect to x; u and z, and piecewise continuous with respect to time t;
 j; j = 1; : : : ;M; are known as the characteristic times of the canonical constraints.
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This problem is denoted as Problem P3. In addition to the formulation above, MISER3.3
allows for a range of other features such as piecewise linear continuous control functions,
jump conditions in the state dynamics and various types of regularization terms in the
objective. We have not detailed these here as they are not used in the computational
work for this thesis. However, the interested reader can nd details in [25].
The continuous inequality constraints (1.15) are eectively innite dimensional con-
straints for the underlying mathematical programming problem that results from the
control parameterization method. An early approach [54] transformed these constraints
into a canonical form (1.14), but the resulting constraints are not dierentiable and can
thus cause numerical diculties for the nonlinear programming solver built into MISER.
A more comprehensive transcription technique which involves two smoothing parameters
was proposed in [56]. This has been coded into the MISER package and the user merely
needs to specify the right hand side of (1.15) and set a switch to invoke this technique.
A more thorough theoretical analysis of the technique which demonstrates that controls
may also be included in the right hand side of (1.15) was given in [32].
The use of multiple characteristic time points in the objective and constraints was rst
proposed in [41] where gradient formula for such functionals were derived. Once again,
these have been incorporated into the MISER software so that the user merely needs to
specify the existence of the multiple characteristic time points.
To use MISER3.3, the user needs to edit a given le of FORTRAN subroutines which
is then compiled into an executable program with the rest of the MISER code. Essentially,
the user has to code up all functions in the dynamics, objective and constraints as well
as their rst order derivatives with respect to the states, controls and system parameters.
MISER then uses these to construct and solve a parameterized version of the problem.
This involves setting up the co-state dierential equations, solving the state and co-state
dynamics numerically, evaluation of the objective and constraints, formulation and eval-
uation of gradients of the objective and constraints with respect to all decision variables
and nally the optimization of the underlying mathematical programming problem via
sequential quadratic programming (SQP) [50]. Note also that other information about a
problem, such as the number of states, controls, system parameters and constraints, the
constraint types, control and system parameter bounds, partitioning of the time horizon
for control parameterization, options for the numerical solution of the dynamics, and op-
tions for the optimization routine are specied by the user in a data le that can be easily
constructed when the executable code is rst invoked.
It should be noted that the numerical solution of general combined optimal control
and optimal parameter selection problems is a complex task even with the availability of
packages like MISER3.3. Convergence to an optimal solution may be slow and some judg-
ment on the part of the user is required to set appropriate parameters for the optimization
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processes and to determine when the number of iterations is sucient. Furthermore, since
the underlying mathematical programming problem is non-convex, convergence may only
lead to locally optimal solutions and it may be necessary to start the process with several
initial guesses to nd a good solution.
In practice, the accuracy of the optimal control obtained by the standard control pa-
rameterization method with piecewise constant controls is often not high, as it is impossi-
ble to know the precise switching times a priori. To obtain higher accuracy, the switching
times of the controls should also be regarded as decision variables, but MISER3.3 does not
allow for this possibility. However, as detailed in the next section, this diculty can be
overcome via a time scaling transformation which was originally proposed in [29]. As we
will see later in the thesis, the same technique can also be employed to allow for variable
characteristic times in both the objective and the constraint functionals.
1.3.4 Time scaling transformation
For ease of notation, we illustrate the application of the technique to Problem P1 only.
Suppose that we implement control parameterization for Problem P1 using the partition
P dened in Section 1.3.1 and the piecewise constant control given by (1.7). We now
want the points in the partition i; i = 1; : : : ; N to be variables also. Thus, we invoke a
well known transformation [30] to map these variable time points to xed points on a new
time horizon [0; N ]. The resulting equivalent problem avoids several numerical diculties
associated with variable switching times [30] and can be solved directly with MISER3.3.
This is achieved by dening a new time variable s 2 [0; N ], a set of equivalent variables
i = i   i 1; i = 1; : : : ; N; (1.16)
and setting
dt(s)
ds
= v(s); (1.17)
where v : [0; N ]! R is a piecewise constant function dened by
v(s) =
NX
i=1
i[i 1;i)(s); (1.18)
which satises the bounds
0  v(s)  T; s 2 [0; N ]: (1.19)
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As before, the indicator function is dened as
[i 1;i)(s) =
8<:1; if s 2 [i  1; i);0; otherwise: (1.20)
Furthermore, we require
t(0) = 0 = 0; (1.21)
and
t(N) = T: (1.22)
Note that i; i = 1; : : : ; N; are now decision variables in the transformed problem and the
values of i; i = 1; : : : ; N; can be easily calculated from i; i = 1; : : : ; N . Furthermore, we
require
0 6 i 6 T; i = 1; : : : ; N: (1.23)
Let ~x(s) = x(t(s)) and ~u(s) = u(t(s)):
Since (1.17) can be re-arranged as dt = v(s)ds; the transformed problem is to choose
a control of the form (1.7) (i.e. choosing both ij and i; i = 1; : : : ; N) to minimize the
objective
~G0 = 0(~x(N)) +
Z N
0
v(s)L0(t(s); ~x(s); ~u(s))ds (1.24)
subject to the dynamic system
_~x(s) = v(s)f(t(s); ~x(t); ~u(s)); (1.25)
dierential equation (1.17), the initial conditions (1.2) and (1.21), the constraints
~Gi = i(~x(N)) +
Z N
0
v(s)Li(t(s); ~x(s); ~u(s))ds
8<:= 0; i = 1; : : : ; qe; 0; i = qe + 1; : : : ; q; (1.26)
the constraint (1.22) and the bounds on v (1.19) and  (1.23). Note that the transformed
problem ts directly into the general MISER3.3 framework. Compared to Problem P2,
the revised problem, denoted as Problem P4, has one additional state, one additional
control function and one additional canonical constraint.
Finally, note that the same time scaling transformation can also be employed for more
general classes of optimal control problems such as Problem P3 described in Section 1.3.3.
CHAPTER 2
Literature Review
2.1 Mathematical modelling of the blood glucose reg-
ulatory system
A range of mathematical models have been proposed in the literature to capture, and,
in many cases, control blood glucose dynamics in the human body. Most of these are
dynamic in nature, either in the form of dierential or dierence equations. They often
include other compounds associated with glucose, such as insulin, glucagon and glyco-
gen. Some models are designed exclusively to determine treatment regimes for Type 1
diabetics while others are intended for both healthy individuals as well as those with a
diabetic impairment. Models also dier in terms of the processes that they capture. For
example, some models simply assume the appearance of glucose in the blood while oth-
ers actually capture the digestive process directly. Models vary greatly in terms of their
complexity, ranging from simple linear models involving just glucose and insulin [1] to
complex nonlinear models which try to capture the chemical changes of the beta cells in
the pancreas [20]. While simple linear models lend themselves to analytic analysis and
the application of standard control algorithms from the engineering disciplines, they do
not capture the rich dynamic behavior of the real process. There is an ever expanding
range of medical treatment options for diabetes beyond the traditional use of insulin.
In order to capture the various eects of these treatments, mathematical models must
include those dynamics which are directly aected by the treatments. In this chapter, we
review a range of existing models and outline their main features.
2.1.1 Bergman minimal model
The Bergman minimal model [10] was proposed around 1980 to allow researchers to
measure the quantitative contributions of pancreatic responsiveness (i.e. the increased
production of insulin by the pancreas) and insulin sensitivity (i.e. the increased uptake
of glucose by cells in response to insulin) to a subject's overall glucose tolerance (i.e. the
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body's ability to revert from high blood glucose levels back to base levels). As both of
these eects lead to a lowering of blood glucose levels, it is generally dicult to measure
their relative contribution. The proposed model is `minimal' in the sense that it is the
simplest physiologically based representation of the blood glucose regulatory system which
can account for the following factors:
(a) observed glucose kinetics when the plasma insulin values are supplied; and
(b) observed insulin kinetics when the plasma glucose values are supplied.
The minimal model was used in [10] to estimate the characteristic parameters of pancreatic
responsiveness and insulin sensitivity of several subjects who underwent an intravenous
glucose tolerance test (IVGTT) and whose plasma glucose and insulin levels were mea-
sured in response to the IVGTT. Up until the results in [10], quantitative analysis of
pancreatic responsiveness and insulin sensitivity was only possible by articially main-
taining constant blood glucose levels (by infusion of glucose during an experiment, known
as glucose clamp) which entailed some risk to the subject. Despite the limited intended
application of the Bergman minimal model as an analysis tool for IVGTT data, its inher-
ent simplicity (it involves only 3 coupled ordinary dierential equations) has led to many
researchers adopting and modifying the model in subsequent publications. In [9], more
than 500 such studies have been identied in the literature. It is also worth noting that the
role of the liver in the blood glucose regulatory system is acknowledged in [10], although
it is not included in the minimal model. Although no direct treatment methods are pro-
posed in [10] for glucose intolerant (i.e.diabetic) subjects, it is noted that once a subject's
pancreatic responsiveness and insulin sensitivity have been identied, specic treatments
can be designed with more condence. The dynamic system takes the following form [12]:
dG
dt
=  p1[G(t) Gb] X(t)G(t) +D(t); (2.1)
dX
dt
=  p2X(t) + p3[I(t)  Ib]; (2.2)
dI
dt
=
8<:[G(t)  h]t  h[I   Ib]; if G(t)  h > 0; n[I   Ib] + u(t); if G(t)  h  0; (2.3)
where
G(t)[mg=dl] = the blood glucose concentration at time t [min];
I(t)[U=ml] = blood insulin concentration at time t (min);
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X(t)[min 1] = a function representing insulin excitable tissue glucose uptake activ-
ity, proportional to insulin concentration in a remote compartment;
Gb[mg=dl] = the subject's basal glucose level;
Ib[U=ml] = the subject's basal insulin level;
D[mg=dl] = exogenous infusion of glucose;
u(t)[U(ml]) = exogenous infusion of insulin; the basal glucose and insulin levels
refer to the intravenous glucose tolerance test (IVGTT) record;
n[min 1] = the time constant for insulin decay;
p1[min
 1] = the insulin independent rate constant of glucose uptake in muscles and
liver;
p2[min
 1] = the rate of decrease in the tissue glucose uptake ability;
p3[(U(ml)min
 2)] = the insulin dependent increase in glucose uptake ability in
tissue per unit of insulin concentration above the basal level;
h[mg=dl]= the pancreatic \target glycaemia";
[(U=ml)=(mg=dl) 1min 1]= the rate of pancreatic release of insulin after the
bolus of glucose concentration above the target "glycaemia".
Here, U is the international unit especially for insulin, such that 1mU = 6:945 10 12M .
Equation (2.1) assumes the appearance of glucose via the digestion of a meal and
two means by which glucose disappears, one related to insulin and the other unrelated.
Equation (2.2) assumes a natural decay of remote insulin and appearance/disappearance
of glucose depending on its current level in relation to a basal level. Equation (2.3)
describes the dynamics of pancreatic insulin release in response to glucose stimulus for
two cases, a healthy person and a diabetic. The term [G(t)   h]t presents endogenous
insulin secretion for a healthy person in the rst case (when G(t)   h > 0) and it does
not appear in the second case which describes the insulin release rate for a diabetic. In
contrast, the term u(t) which represents an exogenous infusion of insulin is added in this
second case.
2.1.2 Models by Cobelli and coworkers
A more comprehensive model of the blood glucose regulatory system which considers
glucagon dynamics alongside insulin dynamics and their interrelation was proposed in [13].
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This model involves three subsystems. The glucose subsystem is described by a one-
compartment model of distribution and metabolism that involves net hepatic glucose
balance (i.e. the dierence between liver glucose production and uptake), renal excretion
of glucose, insulin-dependent glucose utilization (by muscle) and insulin-independent glu-
cose utilization (by the central nervous system). The insulin subsystem is described by a
ve-compartment model that involves pancreatic insulin storage, liver and portal plasma
insulin, plasma insulin and insulin in the interstitial uid. The glucagon subsystem is
described by a one-compartment model that involves plasma glucagon and glucagon in
the interstitial uid.
The authors in [13] acknowledge the diculty of validating complex models against
experimental data. However, they point out that many aspects of their model are based
on results from both whole body and individual organ experiments. Reference [13] also
includes a range of simulations of their model for a variety of dierent scenarios and
demonstrates reasonable results in each case. While acknowledging some shortcomings of
their model, the authors of [13] make an important point which is true for any compre-
hensive mathematical model in the biological sciences: `The usefulness of the model as a
sort of ecient and integrated library of physiological and clinical knowledge in a research
group working both experimentally and theoretically on carbohydrate metabolism can not
be overemphasized'. Despite its complexity (or perhaps because of it), the model in [13]
has not been as widely cited as the Bergman minimal model. Its distribution of insulin
into ve compartments is unique amongst all the models we have studied and this feature
was never carried forward into future models that evolved from the group of researchers
around Claudio Cobelli. A recent example is proposed in [37] where several independent
sub-models are combined. One of these sub-models describes the glucose ingestion and
absorption processes in the digestive system, a dicult task in its own right. The model
in [37] was tted to the results of a comprehensive experiment involving over 200 healthy
and 14 type 2 diabetic subjects who consumed a meal with 3 versions of traceable glucose.
The aim of the resulting model is to serve as a simulation tool for testing various types
of diabetic treatment regimes. For this purpose, a Matlab version of the models, known
as GIM [15], has been created for general use by researchers.
2.2 Early work on diabetes control
There were several publications by M.E. Fisher around 1990 with the aim to derive optimal
strategies for the control of diabetes. Both analytical and numerical solution methods were
employed, including the rst ever application of computational optimal control methods
in this area. In [18], the simple linear dynamic model of [1] was employed to describe the
glucose dynamics while [17] makes use of the nonlinear Bergman minimal model [10]. The
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scenarios tested essentially assumed a type 1 diabetic subject and the requirements were to
reduce an initially high blood glucose level in one case or to deal with a glucose spike due to
a meal ingested in another case. The only means of controlling blood glucose was assumed
to be the external administration of insulin. Some interesting results were obtained,
such as the superiority of single large dose of insulin over a continuous injection but the
underlying models were too simple to justify any conclusions in a realistic environment.
2.3 Blood glucose control for diabetics
Many of the proposed mathematical models for the blood glucose regulatory system were
constructed with the ultimate purpose of determining various ways of controlling glucose
levels for diabetic patients (mainly via appropriate injections of insulin). An excellent
review of a range of control algorithms can be found in [12], where the authors also
discuss in detail the glucose measuring devices and insulin injection equipment used in
clinical settings. We give a brief review of several control methods below.
A range of model free control algorithms has been described in the literature, mainly
in the context of type 1 diabetic treatment. Model free means that the algorithms are
not based on any mathematical model of the glucose regulatory system. Instead, they
generally rely on frequent blood glucose measurements, including the response of blood
glucose levels to known quantities of insulin infusions. Simple versions rely on look up
tables or functional curves based on previous experience while more advanced ones employ
methods popular in engineering such as proportional-integral-derivative (PID) control or
neural network approaches (where a neural network is rst trained on the insulin-glucose
response data) [12]. While these model free algorithms are usually easy to implement
in practice and can, with some experience, lead to good blood glucose control, they are
eectively a black box approach and oer no insights into how the real underlying system
functions [12].
In contrast, model based control methods assume a mathematical model of the glucose
regulatory system and can thus deal with more complicated scenarios such as model
disturbances or other major perturbations of the system. Drawbacks of the model based
approach are that the model may lack validity or accuracy and that models often contain
multiple uncertain parameters that may be dicult to measure in practice. Several recent
approaches are outlined below.
In [46], discrete time model based algorithms for type 1 diabetic patients tted with
closed loop insulin infusion pumps are proposed. A linear state space model is assumed
and used to estimate future output values based on a series of past inputs. This informa-
tion is then used to generate a linear model predictive controller (MPC). This approach
is then enhanced with the use of a Kalman lter for state estimation and the non lin-
18 Literature Review
ear quadratic dynamic matrix control (NLQDMC) technique (which compensates for the
known non linearities of the process). The digital nature of this algorithm lends itself to
possible implementation via micro chips. A similar MPC based approach is used in [36],
where the authors augment the state space model with an additional dierential equation
which models the relationship between the blood glucose levels in the subcutaneous layer
(where measurements are taken from in practice) and in the blood plasma.
A non linear model predictive controller was proposed in [23] with the aim of maintain-
ing normal blood glucose levels in type 1 diabetic patients during fasting conditions. It is
based on the authors' own blood glucose regulatory model which also includes a two com-
partment submodel to represent the absorption of subcutaneously administered insulin.
Other features of the model are of a similar level of complexity as the Bergman minimal
model [10]. An interesting feature of the controller proposed in [23] is the provision of
target trajectories towards the desired normal blood glucose level of 6 (mmol/L). A linear
decrease is prescribed for high blood glucose concentrations while a logistic increase is
prescribed when starting with low concentrations. The actual implementation of the con-
troller in [23] is over discrete time steps. An important point made by the authors of [23]
is that the parameters of their underlying model need to be chosen and tted separately
for every individual patient. Indeed, they may even need to be recalculated for the same
patient over longer time periods. This observation can be readily applied to all models of
the blood glucose regulatory system.
In [39], the authors augment the Bergman minimal model with an additional equation
to describe endogenous insulin production so that they can also capture the behavior of
type 2 diabetic patients. They then derive a proportional derivative (PD) and a model
predictive controller (MPC) on the basis of the augmented model and propose a switch-
ing control strategy which attempts to balance optimal performance with reduced com-
putational complexity and the need to avoid hypoglycemia. Results are shown to be a
signicant improvement over those obtained from more traditional PD controllers. This
is one of the few control papers concerned with type 2 diabetic patients.
Both [47] and [28] propose a similar control approach based on the H1 criterion in
linear control system design. In [28], the linear system is based on a series of set points
derived from the non linear model in [31] (which we will review in more detail in the next
section). In [47], the authors linearized the comprehensive nonlinear model of [53]. Both
algorithms were extensively tested on perturbed versions of their underlying nonlinear
models and found to perform well. An interesting feature of [47] was the inclusion of lac-
tate (which appears in the blood stream in response to moderate exercise) and adrenaline
(which appears in the blood stream in response to nocturnal hypoglycemic episodes) in
their linearized model.
A rather dierent control approach was proposed in [5]. The problem of determining
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an optimal closed loop control for an underlying non linear model of blood glucose can,
in principle, be addressed by dynamic programming. However, the computational cost
of this direct approach is prohibitive for most practical problems. Instead, the authors
of [5] adopt an approximate dynamic programming (ADP) formulation and the solution
is obtained via a neural network approach. Since the neural network can be trained o
line, the overall method is suitable for real time application. Results in [5] show that the
strategy performs signicantly better than other control strategies based on linearized
approximations of the underlying model. In particular, it is better at avoiding the crucial
problem of hypoglycemia. However, the approach was based on a relatively simple version
of the Bergman minimal model and it was not tested in clinical trails.
Despite a large range of control algorithms being available, the utopian notion of an
articial pancreas which requires no intervention is still some time away. In addition to
a control algorithm, such a device also requires continuous blood glucose (BG) sensors
and an insulin pump to deliver the insulin to the subject (patient). While subcutaneous
insulin pumps are nowadays widely used in type 1 diabetics and have proven reliability,
the task of measuring blood glucose levels is more dicult.
Various blood glucose monitoring techniques have been developed to date and they
can be classied into three categories. Firstly, invasive techniques depend on taking
regular blood glucose (BG) samples directly from veins and sending these samples to
a glucose sensor. The time delay due the time taken by the sensor has been reduced
over the years from about 10 minutes to about 50 seconds for modern devices. Because
the BG measurement is done in the actual uid of interest invasive methods have high
accuracy. However, there are some disadvantages such as the need for medical supervision,
signicant loss of blood with frequent sampling, and the risk of infections and thrombosis.
Secondly, there are the minimally invasive techniques. These are safer than invasive
methods because the BG measurement is implemented outside the vascular tree, so it
avoids the risks associated with accessing veins. The basic idea is to measure BG indi-
rectly via accessing veins the subcutaneous (SC) layer. Based on this measurement, one
can deduce BG levels based on the relationship between the subcutaneous glucose and the
plasma glucose levels. Many studies have investigated this relationship [36]. The measure-
ment can be taken via a glucose sensor implanted in the SC tissue or via uid extracted
from the SC space. For the case of sensors implanted into the SC tissue, the measurement
is done in situ by using methods such as amperometry (an example of such a sensor is
the MiniMed Continuous Glucose Monitoring System (CGMS)) or uorescence detection.
The implantable sensors have some advantages due to their small size and portability and
they do not require extraction of SC uid for operation. In contrast, some problems can
occur with implanted sensors such as inammation and membrane biofouling. Biofouling
is a common problem which involves the gradual accumulation of proteins and biological
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organisms on the sensor surface which reduces the accuracy of the sensor signal. Also,
note that the need to compute the BG level from the SC level via a mathematical model
requires some eort and may not always give accurate results.
The last category of BG measurement techniques are the non-invasive ones. Clearly,
any patient would prefer to measure blood glucose by a painless method which does not
require puncturing the skin or other forms of discomfort. An example of a non-invasive
technique is optical spectroscopy. This is based on the optical properties of glucose when
exposed to radiation. In other words, it is possible to determine blood glucose levels by
exposing tissue to radiation. Many studies based on the optical spectroscopy method have
appeared in the literature. A comprehensive review of these methods and their various
applications is given in [12]. Another non-invasive technique is dielectric spectroscopy.
In this technique, a small alternating current (AC), is applied and the impedance of the
tissue to the current ow is recorded as a function of frequency [52]. Skin impedance
is very sensitive to changes in membrane potential which is, in turn, inuenced by the
interaction of glucose with red blood cells. Thus, blood glucose levels can be deduced on
the basis of the impedance data. Noninvasive techniques are still being improved and are
the subject of current research with few clinical applications.
2.4 Model by Liu and Tang
A large proportion of the computational work in this thesis is based on the blood glucose
regulatory model proposed by Liu and Tang in [31]. This nonlinear model is considered
to be of an intermediate level of complexity. It supersedes the Bergman minimal model
by also taking into account the dynamics of glucose and glycogen in the liver as well as
the dynamics of insulin and glucagon receptors at the molecular level, but it has less state
variables than the complex model proposed by Sorenson [53].
The dynamic model in Liu and Tang [31] consists of eight state variables. These state
variables are dened as follows:
x1 = concentration of plasma glucagon (in moles per liter);
x2 = concentration of plasma insulin (in moles per liter);
x3 = intracellular concentration of glucagon (in moles per liter);
x4 = intracellular concentration of insulin (in moles per liter);
x5 = concentration of glucagon receptor (in moles per liter);
x6 = concentration of insulin-bound receptor (in moles per liter);
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x7 = blood concentration of glycogen (in milligrams per liter);
x8 = blood concentration of glucose (in milligrams per liter).
The model can be naturally divided into three subsystems, each of which is described
below. See Figure 2.1 for a graphical representation.
The insulin and glucagon transition subsystem governs x1 and x2. The model assumes
that plasma insulin does not act directly on the glucose metabolism, but instead through
remote cellular insulin. The model also assumes that intracellular insulin does not move
back to plasma. Under these assumptions, the dynamics for x1 are given by
dx1
dt
=  (kp1;1 + kp1;2)x1 + w1; (2.4)
where kp1;1 is a transition rate, k
p
1;2 is a degradation rate, and w1 is the glucagon release
rate (GRR) dened by
w1 =
Gm
1 + b1 exp a1(x8   C5) : (2.5)
Furthermore, the dynamics for x2 are given by
dx2
dt
=  (kp2;1 + kp2;2)x2 + w2; (2.6)
where kp2;1 is a transition rate, k
p
2;2 is a degradation rate, and w2 is the insulin release rate
(IRR) dened by
w2 =
Rm
1 + b2 exp a2(C1   x8) : (2.7)
The fractions w1 and w2 in equations (2.4)-(2.7) model the natural feedback control mech-
anisms in the body. Note that Gm is the maximum glucagon infusion rate, Rm is the
maximum insulin infusion rate, and a1, a2, b1, b2, C1 and C5 are positive constants.
The insulin and glucagon receptor binding subsystem governs x3, x4, x5 and x6. The
model assumes that receptor recycling is a closed subsystem; the synthesis rate of receptors
is equal to their degradation rate. The dynamics for this subsystem are given by
dx3
dt
=  ks1;1x3(R01   x5)  ks1;2x3 +
kp1;1Vpx1
V
; (2.8)
dx4
dt
=  ks2;1x4(R02   x6)  ks2;2x4 +
kp2;1Vpx2
V
; (2.9)
dx5
dt
=  ks1;1x3(R01   x5)  kr1x5; (2.10)
dx6
dt
=  ks2;1x4(R02   x6)  kr2x6; (2.11)
where ks1;1 and k
s
2;1 are the hormone-receptor association rates, k
s
1;2 and k
s
2;2 are the degra-
dation rates, R01 and R
0
2 are the total concentrations of receptors, k
r
1 and k
r
2 are the
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Figure 2.1: A simplied model of the regulatory system for blood glucose (adapted from
reference [31]). Glucose is input from food and the liver, and used by brain and nerve
cells (insulin-independent) and by tissue cells such as muscle, kidney, and fat cells (insulin-
dependent, indicated by the dashed arrow). Glucose is transported to and from liver cells
by the concentration-driven GLUT2, which is insulin-independent. In response to low
blood glucose levels (< 80 mg/dl), the  cells of the pancreas produce the hormone
glucagon. The glucagon initiates a series of activations of kinases (the black arrows
indicate such activations). This ultimately leads to the activation of the enzyme glycogen
phosphorylase, to catalyze the breakdown of glycogen into glucose. In addition, the series
of activations of kinases also result in the inhibition of glycogen synathase, which stops
the conversion of glucose to glycogen. In response to high blood glucose levels (> 120
mg/dl), the  cells of the pancreas secrete insulin. Insulin triggers a series of reactions to
activate glycogen synthase, which catalyzes the conversion of glucose into glycogen.
inactivation rates, Vp is the plasma insulin volume, and V is the cellular insulin volume.
The glucose production and utilization subsystem governs x7 and x8, and thus models
the production of glucose. Plasma glucose has two sources: hepatic glucose produced by
converting glycogen into glucose in the liver represented by f5 dened in equation (2.12)
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and exogenous glucose taken from food represented by G in equation (2.15). Glucose
utilization can be classied into two classes: insulin-independent (by the brain and nerve
cells) (represented by f1 dened in equation (2.16)) and insulin-dependent (by the muscle
and fat cells) (represented by the product of f2 and f3, themselves dened in equations
(2.17) and (2.18)). The dynamics for x7 are given by
dx7
dt
= f4   f5; (2.12)
where
f4 =
k1x6
1 + k2x5
 V
gs
maxx8
kgsm + x8
(2.13)
represents the synthasis of glycogen from glucose and
f5 = k3x5
V gpmaxx7
kgpm + x7
: (2.14)
Here, k1, k2 and k3 are the feedback control gains, V
gs
max is the maximum velocity of
glycogen phosphorylase, V gpmax is the maximum velocity of glycogen synthase, and k
gs
m and
kgpm are the Michaelis-Menton constants.
The dynamics for x8 are given by
dx8
dt
=  f4 + f5   f1   f2f3 +G; (2.15)
where
f1 = Ub

1  exp

  x8
C2

; (2.16)
f2 =
x8
C3
; (2.17)
f3 = U0 +
(Um   U0)x4
C4 + x

4
: (2.18)
Note that U0, Ub, Um, C2, C3, C4 and  are positive constants, and G is the exogenous
glucose intake derived from digesting food. Note also that t is the time in minutes.
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The initial conditions prescribed for the model in Liu and Tang [31] are
x1(0) = 1:4 10 11; (2.19)
x2(0) = 2 6:945 10 12; (2.20)
x3(0) = 0; (2.21)
x4(0) = 0:01 6:945 10 12; (2.22)
x5(0) = 0; (2.23)
x6(0) = 0; (2.24)
x7(0) = 200; (2.25)
x8(0) = 918: (2.26)
The complete model dened by equations (2.4)-(2.26) includes 36 model constants.
The model incorporates a number of features that distinguishes it from earlier ones. In
particular, Liu and Tang assume inherent feedback rates for glucagon and insulin (w1 and
w2, respectively) which model the body's own regulating controls. Based on their model,
Liu and Tang develop a new formula to quantify the insulin sensitivity of a subject and
they also demonstrate that their feedback model is input-output stable. This stability
gives theoretical support to the knowledge that blood glucose in a healthy individual
uctuates in a narrow range and further supports the applicability of the model. Finally,
Liu and Tang proposed an optimal control problem based on their model with a quadratic
performance index, but they considered this problem too dicult to solve because of the
complexities and nonlinearities in the model.
2.5 Contributions of the thesis
As we have clearly shown above, there are already many publications devoted to the prob-
lem of controlling blood glucose in diabetic patients. However, very few of the algorithms
preserved are based directly on underlying nonlinear models and thus they cannot take
full advantage of the assumed nonlinearities. The only contribution of those reviewed
above which uses computational optimal control methods on the basis of a nonlinear
model is [17]. Since its publication, signicant advances have been made in the area of
computational optimal control. In particular, we are now able to deal with problems with
variable decision points in the time horizon and these time points may also appear in the
objective function and in the dynamics.
Thus, the rst aim of this thesis is to demonstrate that computational optimal control
methods can be readily used to determine open loop optimal controls for models of the
blood glucose regulatory system. While open loop controls do not take into account
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modelling errors and uncertainties in systems, they still provide a useful benchmark for
the performance of other more direct control strategies. Using this approach, we can also
test extreme scenarios on models and thus identify their weaknesses.
In Chapter 3, we rst formulate and solve an optimal parameter selection problem in
order to obtain more suitable values for many of the model parameters in the Liu and
Tang model. It is generally acknowledged in biological modelling that model constants
are dicult to determine exactly on the basis of experimental results. In the case of
blood glucose models, it has also been noted that model constants can vary signicantly
between dierent subjects and over time for the same subject. We also show that, unlike
the perception raised in [31], optimal controls for insulin and glucagon are readily obtained
by standard computational methods.
In Chapter 4, our aim is to expand the Liu and Tang model in two ways in order to
develop eective optimal control strategies for the treatment of diabetic subjects. One
of the treatment options is increased levels of exercise. The range of dynamic models
incorporating exercise is limited and we review several examples before adopting one
approach and combining it with the Liu and Tang model. The second form of treatment
is assumed to be via bolus insulin injections. As the Liu and Tang model does not
incorporate insulin injection dynamics, we review a range of potential models and adopt a
suitable candidate. We then formulate a combined optimal control and optimal parameter
problem with the aim of determining combined optimal exercise and insulin treatment
strategies for various patient scenarios. Using a time scaling transformation, we show that
the resulting problem is readily solvable via the optimal control software MISER3.3 .
While our studies are primarily based on the model by Liu and Tang, our overall
methodology and the computational tool we used can be applied to any blood glucose
model. We identify a number of future research directions in Chapter 5 in terms of future
possible changes to the Liu and Tang model in order to incorporate a broader range of
diabetic treatment regimes.

CHAPTER 3
Modelling and Optimal Control of Blood
Glucose Levels in the Human Body
3.1 Introduction
Regulating the blood glucose level is a challenging control problem for the human body.
Abnormal blood glucose levels can cause serious health problems over the short and long
term. Although several mathematical models have been proposed to describe the dy-
namics of glucose-insulin interaction, none has been universally adopted by the research
community. In this chapter, we consider a dynamic model of the blood glucose regula-
tory system originally proposed by Liu and Tang in 2008. This model consists of eight
state variables naturally divided into three subsystems: the glucagon and insulin transi-
tion subsystem, the receptor binding subsystem and the glucose subsystem. The model
contains 36 model parameters, many of which are unknown and dicult to determine
accurately. We formulate an optimal parameter selection problem in which optimal val-
ues for the model parameters must be selected so that the resulting model best ts given
experimental data. We demonstrate that this optimal parameter selection problem can
be solved readily using the optimal control software MISER3.3. Using this approach,
signicant improvements can be made in matching the model to the experimental data.
We also investigate the sensitivity of the resulting optimized model with respect to the
insulin release rate. Finally, we use MISER3.3 to determine optimal open loop controls
for the optimized model.
To date, several mathematical models for the blood glucose regulatory system have
been proposed. These models aim to describe the glucose-insulin interaction within the
human body. The Bergman minimal model (1980) is considered to be the fundamental
model in this area [12]. Several control models, such as proportional-integral-derivative
(PID) control [38], robust servo control [28], and model predictive control (MPC) [23],
have been developed based on the Bergman minimal model. In most of the existing
models, the glucose regulatory system is greatly simplied and only glucose and insulin
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are considered.
Liu and Tang [31] have developed a new feedback control model at the molecular level,
which considers the role of the liver, the glucagon and insulin signaling pathways and the
conversion between glucose and glycogen. However, one of the diculties in working with
this model is that it contains many model parameters whose values are not well-dened.
Thus, in this chapter, we formulate an optimal parameter selection problem that can be
solved using the software package MISER3.3 [25]. As we will see, this approach results in
signicant improvements in matching the model to experimental data.
This chapter is organized as follows. We rst review the dynamic model of blood
glucose levels proposed in [31] in Section 3.2. Then, in Section 3.3, we formulate an
optimal parameter selection problem to determine optimal values for the uncertain model
parameters in the dynamic model. The objective here is to match the model to given
experimental data as closely as possible. For this purpose, we consider three possible
objective functions and solve the resulting problems using MISER3.3. In Section 4.4, we
perform a sensitivity test, as proposed in Liu and Tang [31], on the resulting optimized
model to test its sensitivity with respect to the insulin release rate. In Section 3.5, based
on the optimized model, we formulate an optimal control problem in which the aim is to
optimize the release rate for both insulin and glucose. This optimal control problem can
also be solved using MISER3.3. Finally, we conclude the chapter with a discussion of the
numerical results.
3.2 Mathematical model
The dynamic model in Liu and Tang [31] consists of eight state variables. These state
variables are dened as follows:
x1 = concentration of plasma glucagon (in moles per liter);
x2 = concentration of plasma insulin (in moles per liter);
x3 = intracellular concentration of glucagon (in moles per liter);
x4 = intracellular concentration of insulin (in moles per liter);
x5 = concentration of glucagon receptor (in moles per liter);
x6 = concentration of insulin-bound receptor (in moles per liter);
x7 = blood concentration of glycogen (in milligrams per liter);
x8 = blood concentration of glucose (in milligrams per liter).
3.2 Mathematical model 29
The model can be naturally divided into three subsystems, each of which is described
below.
3.2.1 Insulin and glucagon transition subsystem
This subsystem governs x1 and x2. The dynamics for x1 are given by
dx1
dt
=  (kp1;1 + kp1;2)x1 + w1; (3.1)
where kp1;1 is a transition rate, k
p
1;2 is a degradation rate, and w1 is the glucagon release
rate (GRR) dened by
w1 =
Gm
1 + b1 exp a1(x8   C5) : (3.2)
Furthermore, the dynamics for x2 are given by
dx2
dt
=  (kp2;1 + kp2;2)x2 + w2; (3.3)
where kp2;1 is a transition rate, k
p
2;2 is a degradation rate, and w2 is the insulin release rate
(IRR) dened by
w2 =
Rm
1 + b2 exp a2(C1   x8) : (3.4)
The fractions w1 and w2 in equations (3.1)-(3.4) model the natural feedback control mech-
anisms in the body. Note that Gm is the maximum glucagon infusion rate, Rm is the
maximum insulin infusion rate, and a1, a2, b1, b2, C1 and C5 are positive constants.
3.2.2 Insulin and glucagon receptor binding subsystem
This subsystem governs x3, x4, x5 and x6. The dynamics for this subsystem are given by
dx3
dt
=  ks1;1x3(R01   x5)  ks1;2x3 +
kp1;1Vpx1
V
; (3.5)
dx4
dt
=  ks2;1x4(R02   x6)  ks2;2x4 +
kp2;1Vpx2
V
; (3.6)
dx5
dt
=  ks1;1x3(R01   x5)  kr1x5; (3.7)
dx6
dt
=  ks2;1x4(R02   x6)  kr2x6; (3.8)
where ks1;1 and k
s
2;1 are the hormone-receptor association rates, k
s
1;2 and k
s
2;2 are the degra-
dation rates, R01 and R
0
2 are the total concentrations of receptors, k
r
1 and k
r
2 are the
inactivation rates, Vp is the plasma insulin volume, and V is the cellular insulin volume.
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3.2.3 Glucose production and utilization subsystem
This subsystem governs x7 and x8. The dynamics for x7 are given by
dx7
dt
= f4   f5; (3.9)
where
f4 =
k1x6
1 + k2x5
 V
gs
maxx8
kgsm + x8
; (3.10)
f5 = k3x5
V gpmaxx7
kgpm + x7
: (3.11)
Here, k1, k2 and k3 are the feedback control gains, V
gs
max is the maximum velocity of
glycogen phosphorylase, V gpmax is the maximum velocity of glycogen synthase, and k
gs
m and
kgpm are the Michaelis-Menton constants.
The dynamics for x8 are given by
dx8
dt
=  f4 + f5   f1   f2f3 +G; (3.12)
where
f1 = Ub

1  exp

  x8
C2

; (3.13)
f2 =
x8
C3
; (3.14)
f3 = U0 +
(Um   U0)x4
C4 + x

4
: (3.15)
Note that U0, Ub, Um, C2, C3, C4 and  are positive constants, and G is the exogenous
glucose intake derived from digesting food. Here G is expressed using a piecewise linear
interpolation of the data in Table 3.1 and plotted in Figure 3.1, with the precise expression
given by
G =
(gi   gi 1)(t  ti 1)
t  ti 1 + gi 1; t 2 [ti 1; ti]; i = 1; : : : ; 11: (3.16)
3.2.4 Initial conditions and model constants
We assume that the system is modelled over a 9 hour period, i.e., t 2 [0; 540], where t is
the time in minutes. The initial conditions prescribed for the model in Liu and Tang [31]
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Parameter Value Critical points Value
g0 0 t0 0
g1 69.5950045 t1 60
g2 69.2845842 t2 90
g3 77.4619058 t3 120
g4 83.7348629 t4 150
g5 85.7457293 t5 180
g6 89.2449716 t6 240
g7 87.1436913 t7 300
g8 72.9876913 t8 360
g9 52.7402225 t9 420
g10 37.6143743 t10 480
g11 30.2992243 t11 540
Table 3.1: Parameter values for the exogenous glucose input rate G
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Figure 3.1: Exogenous glucose input rate from the experimental data of Korach-Andre et
al. [27]
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are
x1(0) = 1:4 10 11; (3.17)
x2(0) = 2 6:945 10 12; (3.18)
x3(0) = 0; (3.19)
x4(0) = 0:01 6:945 10 12; (3.20)
x5(0) = 0; (3.21)
x6(0) = 0; (3.22)
x7(0) = 200; (3.23)
x8(0) = 918: (3.24)
The complete model dened by equations (3.1)-(3.24) includes 36 model constants as
listed in Table 3.2. Although Liu and Tang [31] give explicit values for each of these
constants, they also acknowledge that many of these values are merely informed guesses,
usually based on biological understanding or adopted from other publications. In Table
3.2, we have indicated which of the constants are well-dened and which have some
uncertainty as to their true values. Note that the values of some of the constants in Table
3.2 dier from the original denitions given by Liu and Tang in [31]. These changes were
made based on the advice received via personal communication with Liu and Tang. In
particular, we have changed the units of measurement for the parameters ks2;1, R
0
2, C4, Rm
and k1, and we also use dierent values for ki, i = 1; 2; 3. These new values are reported
in Table 3.2. In addition, Liu and Tang gave the following guidance on the behaviour
of some of the uncertain parameters: the degradation rates of glucagon and its receptor
(ks1;2, k
r
1) can be assumed to be the same as the respective rates for insulin (k
s
2;2, k
r
2); the
maximum glucagon infusion rate Gm should be selected to be much smaller than Rm; a1
and b1 should be selected so that the glucagon secretion w1 increases rapidly when the
blood glucose level x8 drops to around 800 mg/l; k
p
2;1 can be assumed to be the same as
kp1;1.
3.3 Parameter estimation
Our goal in this chapter is to optimize the model parameters in (3.1)-(3.24), so that the
model matches experimental data as closely as possible. As in Liu and Tang [31], we
use the experimental data reported in Korach-Andre et al. [27]. This data set consists
of blood glucose measurements from a healthy individual taken after meals. We denote
this data set by f(i; x^i8)g9i=1, where i denotes the i-th observation time and x^i8 denotes
the blood glucose concentration observed at the i-th observation time. The experimental
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Constant Value Unit Status
kp1;1 0.14 min
 1 uncertain
kp2;1 0.14 min
 1 uncertain
kp1;2 0.3 min
 1 well-dened
kp2;2 1/6 min
 1 uncertain
ks1;1 6 107 M 1 min 1 well-dened
ks2;1 6 107 M 1 min 1 well-dened
ks1;2 0.01 min
 1 uncertain
ks2;2 0.01 min
 1 uncertain
kr1 0.2 min
 1 uncertain
kr2 0.2 min
 1 well-dened
R01 9 10 13 M well-dened
R02 3:6114 10 12 M well-dened
vgpmax 80 mg/l/min uncertain
kgpm 600 mg/l well-dened
vgsmax 3:87 10 4 mg/l/min uncertain
kgsm 67 mg/l well-dened
k1 2:76900924 1011 M 1 well-dened
k2 1:1111111 1014 M 1 well-dened
k3 1:1111111 1012 M 1 well-dened
V 11 l uncertain
Vp 3 l uncertain
Ub 7.2 mg/l/min uncertain
U0 4 mg/l/min uncertain
Um 94 mg/l/min uncertain
Gm 2:23 10 10 M/min uncertain
Rm 4:8615 10 10 M/min uncertain
C1 2000 mg/l uncertain
C2 144 mg/l uncertain
C3 1000 mg/l uncertain
C4 5:556 10 10 M/l uncertain
C5 1000 mg/l uncertain
 1.77 - uncertain
a1 0.005 (mg/l)
 1 uncertain
a2 1/300 (mg/l)
 1 uncertain
b1 10 - uncertain
b2 1 - uncertain
Table 3.2: Constants in the dynamic model (3.1)-(3.24), where M denotes moles.
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Figure 3.2: Experimental data from Korach-Andre et al. [27]
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Figure 3.3: Comparison of two blood glucose trajectories: the solid trajectory is the
simulated trajectory from (3.1)-(3.24) using the parameter values in Liu and Tang [31];
the dashed trajectory is the experimental data from Korach-Andre et al. [27]
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i 1 2 3 4 5 6 7 8 9
i 0 60 120 150 180 240 380 420 540
x^i8 900 1785.29 1530.27 1330.88 1300.55 1244.95 1113.53 1078.2 900.72
Table 3.3: Experimental data from Korach-Andre et al. [27]
data is shown in Figure 3.2 and listed in Table 3.3. We assume that the experimental
data can be interpolated linearly as shown in Figure 3.2 to yield the function gexp(t).
Using the original parameter values in Liu and Tang [31], the resulting trajectory for
the blood glucose history is shown in Figure 3.3. We will improve the Liu-Tang model
by formulating an optimal parameter selection problem to nd more appropriate values
for the uncertain model parameters in Table 3.2. In the context of Chapter 1, a pure
optimal parameter selection problem takes the general form of Problem P3, but involving
only system parameters and no control functions. In other words, each uncertain model
parameter in Table 3.2 is associated with a component of the vector of system parameters,
z. To cast the problem into the form of P3, we need to specify the set of feasible system
parameters, Z. To do this, for each uncertain parameter, we need to specify upper and
lower bounds. For parameters V , Ub, U0 and , appropriate bounds were suggested by
Liu and Tang [31] in our personal correspondence as shown in Table 3.4. For the other
parameters, we use an iterative approach as follows. We initially guess the lower and
upper bounds on the basis of the parameter values given in Liu and Tang [31] and solve
the resulting parameter estimation problem. Then, for those parameters whose optimal
value turns out to be equal to the lower or upper bound, we decreased or increased
the respective bound by 10 percent and solved the resulting problem again. This process
continues until all optimal parameter values are contained in the interior of their respective
bound intervals. This iterative approach is necessary because the model (3.1)-(3.24) is
quite sensitive to some of the model parameters. It is dicult to integrate the dynamics
numerically when the parameter values are too far from those in the previous stage.
For the purpose of model matching, we consider three possible objectives and solve
the resulting parameter estimation problems with MISER3.3.
3.3.1 Case 1
In this case, our aim is to match the simulated blood glucose level to the experimental
data gexp(t) over the entire time horizon. Thus, the aim is to determine values of the
uncertain parameters so as to minimize
J1 =
Z 540
0
(x8(t)  gexp(t))2 dt (3.25)
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Parameter Lower bound Upper bound
V 10 25
Ub 4 12
U0 4 12
 1 2
Table 3.4: Lower and upper bounds for V , Ub, U0, and 
subject to the dynamic model dened by equations (3.1)-(3.24).
The resulting optimal values of the uncertain parameters are shown in Table 3.5 and
the glucose trajectory generated from (3.1)-(3.24) using these optimal values is shown
in Figure 3.4. Comparing Figures 3.3 and 3.4, it is clear that the optimal parameter
values yield signicant improvements in model matching. However, there appears to be
some mismatch between the model trajectory and experimental data at the terminal time.
Hence, we consider a modied version of the objective function (3.25) in the next case.
3.3.2 Case 2
Here, we add another term to the objective function that measures the dierence between
the predicted and actual blood glucose levels at the terminal time. Specically, the aim
is to minimize
J2 = w (x8(540)  900:72)2 +
Z 540
0
(x8(t)  gexp(t))2 dt (3.26)
subject to the dynamics (3.1)-(3.24), where the weight w is chosen as w = 1000. The
idea here is to force better agreement between the model output and the experimental
data at the end of the time horizon. The resulting optimal values for the uncertain model
parameters are shown in Table 3.5. As seen from the resulting optimal glucose trajectory
in Figure 3.5, a closer match of the trajectories at the terminal time can be achieved at
the expense of increased error earlier in the time horizon.
3.3.3 Case 3
Since the experimental data in Table 3.3 is only measured at a small number of isolated
times, the actual glucose level between these times is unknown. Thus, our denition of
gexp(t) as a piecewise linear interpolating function and the use of the integral terms in
(3.25) and (3.26) may not be appropriate. An alternative parameter estimation problem
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Figure 3.4: Comparison of two blood glucose trajectories: the solid trajectory is the
simulated trajectory from (3.1)-(3.24) using the optimal parameter values for Case 1; the
dashed trajectory is the experimental data from Korach-Andre et al. [27]
is to choose values for the uncertain model parameters in order to minimize
J3 =
9X
i=1
 
x8(i)  x^i8
2
(3.27)
subject to the dynamics (3.1)-(3.24), where x^i8 and i, i = 1; : : : ; 9, are as dened in Table
3.3. Note that this objective function is not in the standard canonical form due to the
presence of multiple non-integral terms that depend on the state at intermediate times
(called characteristic times in the optimal control literature). Nevertheless, objective
functions of this form can be handled using the techniques developed in [34] and [40],
which have been incorporated into the MISER3.3 software [25].
The resulting optimal model parameter values are shown in Table 3.5. As can be
seen in Figure 3.6, the resulting blood glucose level tracks the individual experimental
measurements very closely, although, as expected, it does not follow the interpolating
function gexp(t) as closely as we observed for Case 1.
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Parameter Original value Case 1 Case 2 Case 3
kp1;1 0.14 1.28929 2.19177 1.37664
kp2;1 0.14 0.100804 0.114719 0.154412
kp1;2 0.3 0.3 0.3 0.3
kp2;2 1/6 0.437605 0.743780 0.743944
ks1;1 6 107 6 107 6 107 6 107
ks2;1 6 107 6 107 6 107 6 107
ks1;2 0.01 7:19985 10 3 2:16 10 3 7:6107 10 2
ks2;2 0.01 9:52782 10 3 8:5 10 3 8:95549 10 3
kr1 0.2 2:59194 10 2 7:776 10 3 2:4 10 1
kr2 0.2 0.2 0.2 0.2
R01 9 10 13 9 10 13 9 10 13 9 10 13
R02 3:6114 10 12 3:6114 10 12 3:6114 10 12 3:6114 10 12
vgpmax 80 25.0197 24.6129 24.7160
kgpm 600 600 600 600
vgsmax 3:87 10 4 3:41805 10 3 5:811 10 3 5:811 10 3
kgsm 67 67 67 67
k1 2:76901 1011 2:76901 1011 2:76901 1011 2:76901 1011
k2 1:11111 1014 1:11111 1014 1:11111 1014 1:11111 1014
k3 1:11111 1012 1:11111 1012 1:11111 1012 1:11111 1012
V 11 10.0004 10.3573 10.0181
Vp 3 2.41375 3.44929 2.77484
Ub 7.2 4 4 7.80699
U0 4 4 4 8.14836
Um 94 227.508 227.972 227.642
Gm 2:23 10 10 2:05367 10 9 3:49116 10 9 1:87341 10 9
Rm 4:8615 10 10 2:29663 10 10 3:98353 10 10 4:22818 10 10
C1 2000 1114.19 1114.07 1114.29
C2 144 345.384 345.434 345.378
C3 1000 1061.82 1061.77 1061.77
C4 5:556 10 10 1:9556 10 9 3:32383 10 9 3:28142 10 9
C5 1000 1124.67 1124.67 1124.68
 1.77 1.14055 1.17821 1.33999
a1 0.005 3:48467 10 2 5:9238 10 2 5:9238 10 2
a2 1/300 1:45946 10 2 8:59508 10 3 8:70603 10 3
b1 10 11.4710 11.4664 11.4667
b2 1 1.15002 1.1893 1.955
Table 3.5: Comparing the optimized parameter values with the values in [31]
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Figure 3.5: Comparison of two blood glucose trajectories: the solid trajectory is the
simulated trajectory from (3.1)-(3.24) using the optimal parameter values for Case 2; the
dashed trajectory is the experimental data from Korach-Andre et al. [27]
3.4 Model sensitivity
In Liu and Tang [31], a sensitivity test was performed by doubling and halving the in-
sulin feedback rate and observing the corresponding model response. For comparison, we
perform the same sensitivity test on the model with the optimized parameters from Case
1. This involves replacing the original insulin feedback rate w2 in (3.4) by
w2 =
2Rm
1 + b2 exp a2(C1   x8) ; (3.28)
and
w2 =
1
2
Rm
1 + b2 exp a2(C1   x8) ; (3.29)
respectively. The resulting blood glucose levels are shown in Figures 3.7 and 3.8, respec-
tively. Compared to the corresponding gures in Liu and Tang [31], the glucose levels
in Figures 3.7 and 3.8 are further away from the experimental measurements. This is
expected, since optimizing the model parameters will generally lead to a more sensitive
model. Also, these results agree with the intuitive understanding of the blood glucose
regulatory system in terms of the eects of changing insulin levels.
While we do not pursue this option here, note that it is possible to formulate a modi-
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Figure 3.6: Comparison of two blood glucose trajectories: the solid trajectory is the
simulated trajectory from (3.1)-(3.24) using the optimal parameter values for Case 3; the
dashed trajectory is the experimental data from Korach-Andre et al. [27]
ed optimal parameter selection problem where part of the objective is to minimize the
sensitivity of the model with respect to various disturbances of the type considered here.
See [33] for details.
3.5 Optimal insulin and glucose release rates
The feedback controls (3.2) and (3.4) model the physiology of the pancreas. Liu and
Tang [31] have suggested that these natural feedback controls may not be \optimal" in
the sense of regulating the blood glucose level. They formulated a quadratic optimal
control problem which seeks to nd the corresponding optimal open loop controls but
were not able to solve this problem. In this section, we demonstrate that the optimal
open loop controls for the insulin and glucose release rates can be readily calculated
using the MISER3.3 software [25]. We replace the closed loop controls w1 and w2 by
corresponding open loop controls u1 and u2, respectively. Thus, equations (3.1) and (3.3)
become, respectively,
dx1
dt
=  (kp1;1 + kp1;2)x1 + u1; (3.30)
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Figure 3.7: Blood glucose level when w2 is dened by (3.28).
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Figure 3.8: Blood glucose level when w2 is dened by (3.29).
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Figure 3.9: Optimal blood glucose trajectory corresponding to the optimal solution in
Section 3.5.
and
dx2
dt
=  (kp2;1 + kp2;2)x2 + u2: (3.31)
We assume that both u1 and u2 are parameterized as piecewise linear continuous func-
tions in accordance with the control parameterization method ( [30], [55]). The objective
function (adopted from the suggestion in [31]) is given by:
J =
Z 540
0
f(x8(t)  918)2 + u21(t) + u22(t)gdt: (3.32)
This objective function penalizes both control expenditure and blood glucose deviation
from the initial level. The problem is to minimize (3.32) subject to the dynamic model
(3.1)-(3.24) with the optimized parameters from Case 1 (and with (3.1) and (3.3) replaced
by (3.30) and (3.31)). As the model is quite sensitive to changes in u1 and u2, we use a
homotopy approach with the initial guesses of u1 and u2 as w1 and w2 (from the Case 1
optimized the model), respectively. We initially imposed tight lower and upper bounds on
u1 and u2 around the initial guesses. These bounds were then slowly relaxed over a series
of optimization iterations until no more improvement in the objective was observed.
The optimal blood glucose trajectory is shown in Figure 3.9 and the optimal controls
are shown in Figures 3.10 and 3.11. As can be seen from Figure 3.9, the blood glucose
level corresponding to the optimal open loop controls remains very close to the initial
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Figure 3.10: The optimal glucagon release rate.
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Figure 3.11: The optimal insulin release rate.
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blood glucose level (918 mg=l= 5.1 mmol=l) over the entire time horizon. This clearly
demonstrates that excellent glucose control is achievable with the open loop formulation.
Note that this is a purely theoretical study to determine whether open loop blood glucose
control is possible and what the corresponding controls look like. In practice, delivery of
glucagon or insulin in this manner is not practical. However, the blood glucose response
is quite dierent from that observed in experimental results. This raises the question of
why the blood glucose regulatory system in the human body does not follow the `optimal'
approach calculated via the open loop formulation. One should note that the glucose
regulatory system forms only one part of a more complex metabolic system that controls
the human body. There are probably sound reasons why elevated blood glucose levels
occur in humans after the ingestion of a meal, but these are not reected in the glucose
regulatory model considered here.
3.6 Conclusions
We have solved a complex model matching problem in which a glucose regulatory model
must be tted to experimental data to minimize total modelling error. We investigated
several dierent model matching objectives and found that signicant improvement in
matching the model to experimental data was achieved in all cases when compared to
the results in Liu and Tang [31]. It is dicult for us to judge the relative merits of
these objectives and the ultimate choice is best left to experts who are more familiar
with the use of the model in relation to the real physical system. Nevertheless, we have
demonstrated that the proposed model matching strategy yields very good results in this
scenario and it should be used more widely for other biological systems.
As expected, we also found that the optimized model was more sensitive to changes in
the insulin release rate. Finally, we showed that open loop optimal controls can be readily
calculated for the glucose regulatory system. The resulting glucose proles do not match
real proles observed experimentally, which suggests that there may be other mechanisms
at play in the real system which are not accounted for in the mathematical model.
Future work will consider the implementation of the glucose regulatory model for
diabetic individuals and how their conditions can be controlled optimally.
CHAPTER 4
Insulin Injection and Exercise Scheduling for
Diabetics: An Optimal Control Model
In this chapter, we develop a composite dynamic model for simulating the eects of ex-
ercise and subcutaneous insulin injections on the blood glucose regulatory system. This
model consists of 12 state variables naturally divided into four subsystems|the glucagon
and insulin transition subsystem, the receptor binding subsystem, the glucose subsys-
tem and the exercise subsystem|with dynamic system switches at the insulin injection
times. We formulate an optimal control problem in which the aim is to determine optimal
injection times, optimal injection volumes and optimal exercise regimes to regulate the
blood glucose level. A numerical approach, based on control parameterization and the
time scaling transform, is then developed for solving the optimal control problem. Nu-
merical results for a series of ve scenarios show that optimal treatment regimes can be
readily determined via the proposed approach. Good blood glucose can be achieved given
moderate levels of treatment.
4.1 Introduction
Insulin was rst isolated and puried as a treatment for diabetes in 1920. However, a
permanent cure has been elusive until this day. Type 1 diabetes is managed through the
use of analogue insulin as well as targeted diet and exercise. Type 2 diabetes treatment
may start with non-insulin medication, which stimulates the body's own insulin generation
or reduces insulin resistance. A controlled diet may be sucient to treat very early cases
of type 2 diabetes. However, as the disease progresses, insulin treatment will eventually be
required. Moreover, due to issues such as age, excessive weight and high blood pressure,
the level of exercise may be restricted for some patients, especially if they have other
health problems such as heart disease and risk of strokes.
The three most common methods for administering insulin are the intra-peritoneal,
subcutaneous (SC) and intravenous (IV) injections [12]. SC injection is the most common
45
46 Insulin Injection and Exercise Scheduling for Diabetics
method and involves either direct injection at the site, or injection via an external insulin
pump, which provides a steady stream of insulin throughout the day. On the other hand,
medical supervision is required to receive IV insulin injections via veins and surgical
administration is required to implant an insulin pump in the peritoneum (the serous
membrane lining the walls of the abdominal and pelvic cavities (parietal peritoneum)) in
order to deliver intra-peritoneal insulin. In addition, SC injections are a less expensive
method for patients to receive their daily injections. Thus, in this chapter, we focus on the
subcutaneous injection method. Many factors can aect the insulin absorption process
such as temperature, insulin concentration and volume and injection site and depth. In
addition, the insulin state can be hexameric, dimeric or monomeric which aects the time
taken for the insulin preparation to be absorbed into blood plasma. We review several
mathematical models of insulin absorption and choose one suitable for incorporation into
the existing model.
In this chapter, we extend the mathematical model of the human blood glucose regu-
latory system originally proposed by Liu and Tang [31]. Specically, we focus on creating
a more complete model that captures the eect of exercise and subcutaneous insulin
injections on the blood glucose level for diabetic individuals. Based on the composite
model, we formulate an optimal control problem which seeks to minimize the dierence
between the blood glucose level for a diabetic individual and a desired trajectory. To
generate accurate values for the optimal insulin injection times, we apply a time scaling
transformation technique ( [30], [34]). Numerical results show that, on the basis of these
formulations, good blood glucose control can be readily achieved for a variety of desired
blood glucose trajectories with the use of the MISER3.3 optimal control software [25].
This chapter is organized as follows. We rst review the model described in [31]
and [3] in Section 4.2. Then, in Section 4.3, we propose extensions of the model in
Section 4.2 which take into account the eects of both insulin injections and exercise. In
Section 4.4, we formulate a combined optimal control and optimal parameter selection
problem with the aim of following a desired blood glucose prole as closely as possible. In
order to allow for the numerical optimization of the injection times, we adopt the control
parameterization and time scaling transformation methods described in Chapter 1. We
then solve the transformed problem for a variety of scenarios using the optimal control
software MISER3.3. [25] in Section 4.5. Finally, we conclude the chapter with a discussion
of the numerical results and suggestions for future work.
4.2 Original model
We review once more the dynamic model in Liu and Tang [31] consisting of eight state
variables. These state variables are dened as follows:
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x1 = concentration of plasma glucagon (in moles per liter);
x2 = concentration of plasma insulin (in moles per liter);
x3 = intracellular concentration of glucagon (in moles per liter);
x4 = intracellular concentration of insulin (in moles per liter);
x5 = concentration of glucagon receptor (in moles per liter);
x6 = concentration of insulin-bound receptor (in moles per liter);
x7 = blood concentration of glycogen (in milligrams per liter);
x8 = blood concentration of glucose (in milligrams per liter).
The model can be naturally divided into three subsystems, as described in the following
subsections (see [31] and [3] for more details).
4.2.1 Insulin and glucagon transition subsystem
This subsystem governs state variables x1 and x2. The dynamics for x1 are given by
dx1
dt
=  (kp1;1 + kp1;2)x1 + w1; (4.1)
where kp1;1 is a transition rate, k
p
1;2 is a degradation rate, and w1 is the glucagon release
rate (GRR) dened by
w1 =
Gm
1 + b1 exp a1(x8   C5) : (4.2)
The dynamics for x2 are given by
dx2
dt
=  (kp2;1 + kp2;2)x2 + w2; (4.3)
where kp2;1 is a transition rate, k
p
2;2 is a degradation rate, and w2 is the insulin release rate
(IRR) dened by
w2 =
Rm
1 + b2 exp a2(C1   x8) : (4.4)
The fractions w1 and w2 in equations (4.1)-(4.4) model the natural feedback control mech-
anisms in the body. Note that Gm is the maximum glucagon infusion rate, Rm is the
maximum insulin infusion rate, and a1, a2, b1, b2, C1 and C5 are positive constants.
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4.2.2 Insulin and glucagon receptor binding subsystem
This subsystem governs state variables x3, x4, x5 and x6. The dynamics for this subsystem
are given by
dx3
dt
=  ks1;1x3(R01   x5)  ks1;2x3 +
kp1;1Vpx1
V
; (4.5)
dx4
dt
=  ks2;1x4(R02   x6)  ks2;2x4 +
kp2;1Vpx2
V
; (4.6)
dx5
dt
=  ks1;1x3(R01   x5)  kr1x5; (4.7)
dx6
dt
=  ks2;1x4(R02   x6)  kr2x6; (4.8)
where ks1;1 and k
s
2;1 are the hormone-receptor association rates, k
s
1;2 and k
s
2;2 are the degra-
dation rates, R01 and R
0
2 are the total concentrations of receptors, k
r
1 and k
r
2 are the
inactivation rates, Vp is the plasma insulin volume, and V is the cellular insulin volume.
4.2.3 Glucose production and utilization subsystem
This subsystem governs state variables x7 and x8. The dynamics for x7 are given by
dx7
dt
= f4   f5; (4.9)
where
f4 =
k1x6
1 + k2x5
 V
gs
maxx8
kgsm + x8
; (4.10)
f5 = k3x5
V gpmaxx7
kgpm + x7
: (4.11)
Here, k1, k2 and k3 are the feedback control gains, V
gs
max is the maximum velocity of
glycogen phosphorylase, V gpmax is the maximum velocity of glycogen synthase, and k
gs
m and
kgpm are Michaelis-Menton constants.
The dynamics for x8 are given by
dx8
dt
=  f4 + f5   f1   f2f3 +G; (4.12)
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where
f1 = Ub

1  exp

  x8
C2

; (4.13)
f2 =
x8
C3
; (4.14)
f3 = U0 +
(Um   U0)x4
C4 + x

4
: (4.15)
Here, U0; Ub; Um; C2; C3; C4 and  are positive constants, and G is the exogenous glucose
input rate. As in the earlier chapters, we use the experimental data of Korach-Andre et
al. [27] to dene G.
4.2.4 Initial conditions and model constants
We assume that the system is modelled over a 9 hour period, i.e., t 2 [0; 540], where t is
the time in minutes. The initial conditions prescribed for the model are
x1(0) = 1:4 10 11; (4.16)
x2(0) = 2 6:945 10 12; (4.17)
x3(0) = 0; (4.18)
x4(0) = 0:01 6:945 10 12; (4.19)
x5(0) = 0; (4.20)
x6(0) = 0; (4.21)
x7(0) = 200; (4.22)
x8(0) = 918: (4.23)
The complete model dened by equations (4.1)-(4.23) includes 36 model constants. In
Chapter 3, we formulated an optimal parameter selection problem to optimize these con-
stants, so that the model matches desired blood glucose data from Korach-Andre et al. [27]
as closely as possible. This data set consists of blood glucose measurements from a healthy
individual taken after a meal. We denote this data set by f(i; x^i8)g9i=1, where i denotes
the i-th observation time and x^i8 denotes the blood glucose concentration observed at
the i-th observation time. This blood glucose prole is shown in Figure 4.1 and the data
points are listed in Table 4.1. We assumed that the experimental data can be interpolated
linearly as shown in Figure 4.1 to yield the function gexp(t). A good match between the
model and the desired data in [27] was achieved in Chapter 3 and the optimized values
of the model constants are listed in Table 4.2.
50 Insulin Injection and Exercise Scheduling for Diabetics
 800
 1000
 1200
 1400
 1600
 1800
 2000
 0  100  200  300  400  500  600
B l
o o
d  
G
l u
c o
s e
 L
e v
e l
 ( m
g / l
)
t
gexp
Figure 4.1: The desired blood glucose data from Korach-Andre et al. [27]
i 1 2 3 4 5 6 7 8 9
i 0 60 120 150 180 240 380 420 540
x^i8 900 1785.29 1530.27 1330.88 1300.55 1244.95 1113.53 1078.2 900.72
Table 4.1: The desired data from Korach-Andre et al. [27]
4.3 New composite model with exercise and insulin
injections
To adopt the Liu and Tang model to a diabetic subject, we must assume that the natural
insulin release rate dened by equation (4.4) is impaired. For a type 1 diabetic, the
maximum insulin release rate should be chosen as Rm = 0 in model (4.1)-(4.23). Also,
Rm 2 (0; 1) can be used to model type 2 diabetics with varying degrees of severity of the
condition.
4.3.1 SC injections
A variety of mathematical models for the absorption of insulin from subcutaneous (SC)
injections into blood plasma have been proposed in the literature. There is a signicant
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Constant Value Unit
kp1;1 1.28929 min
 1
kp2;1 0.100804 min
 1
kp1;2 0.3 min
 1
kp2;2 0.437605 min
 1
ks1;1 6 107 M 1 min 1
ks2;1 6 107 M 1 min 1
ks1;2 7:19985 10 3 min 1
ks2;2 9:52782 10 3 min 1
kr1 2:59194 10 2 min 1
kr2 0.2 min
 1
R01 9 10 13 M
R02 3:6114 10 12 M
vgpmax 345.384 mg/l/min
kgpm 600 mg/l
vgsmax 3:41805 10 3 mg/l/min
kgsm 67 mg/l
k1 2:76901 1011 M 1
k2 1:1111111 1014 M 1
k3 1:1111111 1012 M 1
V 10.0004 l
Vp 2.41375 l
Ub 4 mg/l/min
U0 4 mg/l/min
Um 227.508 mg/l/min
Gm 2:05367 10 9 M/min
Rm 2:29663 10 10 M/min
C1 1:11419 10 3 mg/l
C2 345.384 mg/l
C3 1061.82 mg/l
C4 1:9556 10 9 M/l
C5 1124.67 mg/l
 1.14055 -
a1 0.0348467 (mg/l)
 1
a2 0.0145946 (mg/l)
 1
b1 11.471 -
b2 1.15002 -
Table 4.2: Optimized values for the model constants
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Insulin type
Parameter
s a b Vd
Short acting (soluble) 2 4:31965 105 102 12 10 6
Intermediate acting (NPH) 2 1:5550756 106 294 12 10 6
long acting (ultralente) 2.5 0 780 12 10 6
Unit - min/M min l
Table 4.3: Berger model parameters for dierent types of insulin; intermediate, short and
long acting insulin
range in the complexity of these models, starting with a simple single pool model involving
a delay term to approximate the absorption of fast acting insulin [26]. Trajanski et al. [57]
present a far more complex model where the diusion of insulin from the injection site is
approximated via the transition across a series of concentric spherical shells. This leads
to a series of partial dierential equations and, while accurate results can certainly be
achieved, there is a signicant computational cost associated with this model. A detailed
review of the various absorption models is given in [44]. After careful consideration of
the suitability of each of these models for our purposes and, guided by the conclusions
in [44], we settled on the model rst proposed in Berger et al. [8]. Briey, in this model
the amount of absorbed insulin from the SC injection depot, A(t), is assumed to be given
by
A(t) = 1  t
s
(T50)s + ts
; (4.24)
where t is the time elapsed since the injection and T50 is the duration required to reach a
50% absorption of the injected insulin. This is given by
T50 = aD + b; (4.25)
where D is the insulin dose, and s, a and b are constants which assume dierent values for
dierent insulin preparations. Table 4.3 shows these parameter values for dierent types
of insulin. The time derivative of A(t), multiplied by the injection dose, then gives the
input ux of injected insulin into the plasma,
ts 1s(T50)sD
Vd((T50)s + ts)2
; (4.26)
where Vd is the plasma insulin distribution volume.
We now allow for up toM SC insulin injections over the time horizon [0; T ]. Each one
of these has an individual eect on the plasma glucose concentration and this is modelled
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by replacing equation (4.3) with
dx2
dt
=  (kp2;1 + kp2;2)x2 + w2 +
MX
i=1
Ii(t); (4.27)
where
Ii(t) =
si(t  ti)si 1(Ti)siDiH(t  ti)
Vd((Ti)si + (t  ti)si)2 ; i = 1; : : : ;M; (4.28)
and ti; i = 1; : : : ;M; are the insulin injection times and H is the Heaviside step function
dened by
H(t) =
8<:0; if t < 0;1; if t  0: (4.29)
Furthermore, Ti, i = 1; : : : ;M; are the durations needed for a 50% absorption of the
insulin injected at time ti, dened by
Ti = aiDi + bi; i = 1; : : : ;M; (4.30)
where Di, measured in moles (M), is the insulin dose and ai , bi and si are specic to the
type of insulin preparation administrated at time ti. We assume that both the timing
of each injection, ti, and the corresponding dosage, Di; i = 1; : : : ;M are variables to be
determined while the insulin type (i.e. the choice of each ai; bi and si) is specied by the
user. Note that we have bounds on each dosage, i.e.
0 6 Di 6 Di;max; i = 1; : : : ;M: (4.31)
4.3.2 Exercise modelling
It is well known that physical exercise has a signicant eect on blood glucose levels.
Indeed, one of the common ways to deal with mild cases of Type 2 diabetes is to prescribe
increased exercise for patients along with sensible changes in diet. It is thus surprising
to see that attempts to incorporate the eects of exercise into glucose-insulin dynamic
models have only appeared in the literature relatively recently. This, together with the
fact that most of the existing approaches have little to no overlap, seems to indicate that
the task is not an easy one and that there are likely to be multiple pathways through
which exercise impacts both glucose and insulin levels in the blood. In [16], the impact of
exercise is modelled rather simply by perturbing coecients in the well known Bergman
minimal model [10]. The main aim in [16] is to study the stability properties of equilibria
for dierent scenarios. Reference [11] follows a similar approach and also introduces some
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additional dynamic states (energy consumption and insulin action). The main focus of [11]
was to t the resulting model to results from a clinical study. The authors of [22] start with
a dierent glucose-insulin model [53] and emphasize the importance of the redistribution
of blood ows around the body during periods of exercise. None of the models mentioned
so far lend themselves to incorporation with the model described in Section 4.2, as they
were all based on much simpler glucose-insulin models involving only 3 state variables.
Reference [49] introduces a much more comprehensive model. This takes into account the
important role of free fatty acids (FFAs) in the blood stream as a source of energy for
the body. It is argued that there are important interactions between the levels of FFAs,
insulin and exercise which have not been accounted for in previous models. While we are
not incorporating the complete model from [49] into the one from Section 4.2 (this would
be an interesting challenge for future studies), we are adopting several aspects related to
the impact of exercise. First, it is argued that exercise promotes a clearance of insulin
in the blood stream since this results in higher glucose production in the liver which is
needed to provide energy. Mathematically, this is modelled as a second order eect with
the dynamics
dx9
dt
= mpv(uex   x9); (4.32)
dx10
dt
= mIU1x9  mIU2x10; (4.33)
where x9 2 [0; 100] represents the current percentage of the maximum rate of oxygen
consumption for an individual (which, in turn, is assumed to be linearly proportional to
the energy expenditure). Here, uex 2 [0; 100] is the rate of oxygen consumption due to
exercise (itself measured as a percentage of the maximum rate of oxygen consumption for
an individual) and x10 is the rate at which insulin is cleared from the blood due to this
eect. Moreover, mpv and mIU1 and mIU2 are model constants whose values are listed in
Table 4.4. Thus, equation (4.27) is modied as follows
dx2
dt
=  (kp2;1 + kp2;2)x2 + w2 +
MX
i=1
Ii   x10x2; (4.34)
The authors of [49] also indicate that exercise induces an increase in the glucose uptake
rate by the working muscles. Furthermore, the rate of glucose production is also in-
creased due to an accelerated rate of glycogenolysis (conversion of glycogen into glucose-
6-phospate which is further converted to glucose). These eects are modelled by the
following dynamics,
dx11
dt
= mGU1x9  mGU2x11; (4.35)
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Constant Value Unit
mpv 0.8 min
 1
mIU1 2:8176 10 3 min 2
mIU2 1.7354 min
 1
mGU1 2:1874 10 3 mg/(kg min2)
mGU2 5:8974 10 2 min 1
mGP1 9:152 10 4 mg/(kg min2)
mGP2 1.3073 min
 1
W 32001.46 kg/l
Table 4.4: Parameter values related to exercise eect on glucose and insulin dynamics
dx12
dt
= mGP1x9  mGP2x12; (4.36)
where x11 and x12 represent the exercise induced glucose uptake and production rates,
respectively. Furthermore, mGU1, mGU2, mGP1 and mGP2 are constants whose values are
also listed in Table 4.4. Finally, the eects are incorporated into blood glucose dynamic
equation (4.12) as follows.
dx8
dt
=  f4 + f5   f1   f2f3 +G+W (x12   x11); (4.37)
where W is a model constant whose value is also given in Table 4.4.
4.3.3 Summary of the revised model
In summary, the dynamical model is described as follows. The dynamics for x1 and x2
are
dx1
dt
=  (kp1;1 + kp1;2)x1 + w1; (4.38)
where w1 is dened by equation (4.2), and
dx2
dt
=  (kp2;1 + kp2;2)x2 + w2 +
MX
i=1
Ii   x10x2; (4.39)
where w2 and Ii are dened by equations (4.4) and (4.28), respectively.
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The dynamics for x3, x4, x5 and x6 are
dx3
dt
=  ks1;1x3(R01   x5)  ks1;2x3 +
kp1;1Vpx1
V
; (4.40)
dx4
dt
=  ks2;1x4(R02   x6)  ks2;2x4 +
kp2;1Vpx2
V
; (4.41)
dx5
dt
=  ks1;1x3(R01   x5)  kr1x5; (4.42)
dx6
dt
=  ks2;1x4(R02   x6)  kr2x6: (4.43)
The dynamics for x7 and x8 are
dx7
dt
= f4   f5; (4.44)
dx8
dt
=  f4 + f5   f1   f2f3 +G+W (x12   x11); (4.45)
where f1   f5 and G are dened by equations (4.13), (4.14), (4.15), (4.10), (4.11) and
(3.16), respectively.
The exercise subsystem which governs state variables x9, x10, x11 and x12 is
dx9
dt
= mpv(uex   x9); (4.46)
dx10
dt
= mIU1x9  mIU2x10; (4.47)
dx11
dt
= mGU1x9  mGU2x11; (4.48)
dx12
dt
= mGP1x9  mGP2x12: (4.49)
The system (4.38)-(4.49) is subject to the following initial conditions.
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x1(0) = 1:4 10 11; (4.50)
x2(0) = 2 6:945 10 12; (4.51)
x3(0) = 0; (4.52)
x4(0) = 0:01 6:945 10 12; (4.53)
x5(0) = 0; (4.54)
x6(0) = 0; (4.55)
x7(0) = 200; (4.56)
x8(0) = 918; (4.57)
x9(0) = 0; (4.58)
x10(0) = 0; (4.59)
x11(0) = 0; (4.60)
x12(0) = 0: (4.61)
The complete composite model dened by equations (4.38)-(4.61) includes the model
constants listed in Tables 4.2, 4.3 and 4.4. We again assume that the system is modelled
over a 9 hour period, i.e., t 2 [0; 540], where t is the time in minutes.
4.4 Optimal control
4.4.1 Problem statement
We rst formulate a combined optimal control and optimal parameter selection problem
based on the composite model (4.38)-(4.61) for a diabetic individual. Our aim is to match
the subject's blood glucose level with a desired blood glucose prole gd(t) over the entire
time horizon. Thus, we need to choose injection times ti; i = 1; : : : ;M; injection dosages
Di; i = 1; : : : ;M; and an exercise regime uex(t), t 2 [0; 540], with the aim to minimize
J =
Z 540
0
(x8(t)  gd(t))2 dt (4.62)
subject to the dynamics (4.38)-(4.61), subject to the control bounds
0 6 uex(t) 6 100; (4.63)
and subject to
0 6 ti 6 540; i = 1; : : : ;M (4.64)
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as well as the bounds on the dosages equation (4.31).
4.4.2 Control parameterization
For computational purposes, we assume that uex(t) is a piecewise constant function dened
over a partition P = f0; 1; : : : ; Ng with 0 = 0, N = 540 and i 1 6 i; i = 1; : : : ; N;
where N is the number of intervals in the partition chosen by the user. Thus, uex(t) may
be written as
uex(t) =
NX
i=1
i[i 1;i)(t); (4.65)
where i is the chosen value of uex in the i-th interval, with
0 6 i 6 100; i = 1; : : : ; N; (4.66)
and
[i 1;i)(t) =
8<:1; if t 2 [i 1; i);0; otherwise. (4.67)
For convenience, note that we also assume that the insulin injection times ti; i = 1; : : : ;M;
coincide with some of the switching times of uex, i.e.
ti = ki ; i = 1; : : : ;M; (4.68)
where ki 2 K = fk1; k2; : : : ; kMg  f0; 1; : : : ; Ng . Naturally, we also assume that
N >> M .
4.4.3 Time scaling transformation
As noted above, MISER3.3 is not equipped to handle the variable time points i; i =
1; : : : ; N . Thus, we invoke a well known transformation [30] to map these variable time
points to xed points in a new time horizon [0; N ]. This is achieved by dening a new
time variable s 2 [0; N ] and setting
dt(s)
ds
= v(s); (4.69)
where
v(s) =
NX
i=1
i[i 1;i](s); (4.70)
4.4 Optimal control 59
and i = i   i 1; i = 1; : : : ; N: Furthermore, we require
t(0) = 0 = 0 (4.71)
and
t(N) = T = 540: (4.72)
Note that i; i = 1; : : : ; N; are now decision variables in the transformed problem and the
values of i; i = 1; : : : ; N; can be easily calculated from i; i = 1; : : : ; N . Furthermore, we
require
0 6 i 6 T = 540; i = 1; : : : ; N; (4.73)
We adopt the notation ~xi(s) = xi(t(s)); i = 1; : : : ; 12; ~gd(s) = gd(t(s)) and ~uex(s) =
uex(t(s)). Under the time scaling transformation, the dynamic system can be described
as follows. The dynamics for x1 and x2 become
d~x1
ds
= ( (kp1;1 + kp1;2)~x1 + w1)v; (4.74)
d~x2
ds
= ( (kp2;1 + kp2;2)~x2 + w2 +
MX
i=1
~Ii   ~x10~x2)v; (4.75)
where w1; w2 are as dened previously in equations (4.2) and (4.4), respectively. Moreover,
~Ii(s) = Ii(t(s)); i = 1; : : : ;M; The dynamics for x3, x4, x5 and x6 become
d~x3
ds
= ( ks1;1~x3(R01   ~x5)  ks1;2~x3 +
kp1;1Vp~x1
V
)v; (4.76)
d~x4
ds
= ( ks2;1~x4(R02   ~x6)  ks2;2~x4 +
kp2;1Vp~x2
V
)v; (4.77)
d~x5
ds
= ( ks1;1~x3(R01   ~x5)  kr1~x5)v; (4.78)
d~x6
ds
= ( ks2;1~x4(R02   ~x6)  kr2~x6)v: (4.79)
The dynamics for x7 and x8 become
d~x7
ds
= (f4   f5)v; (4.80)
d~x8
ds
= ( f4 + f5   f1   f2f3 + ~G+W (~x12   ~x11))v; (4.81)
where f1; : : : ; f5 are dened by (4.13), (4.14), (4.15), (4.10) and (4.11), respectively, and
~G(s) = G(t(s)).
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The exercise subsystem dynamics become
d~x9
ds
= mpv(~uex   ~x9)v; (4.82)
d~x10
ds
= (mIU1~x9  mIU2~x10)v; (4.83)
d~x11
ds
= (mGU1~x9  mGU2~x11)v; (4.84)
d~x12
ds
= (mGP1~x9  mGP2~x12)v: (4.85)
The dynamics of the new state variable t(s) is
dt(s)
ds
= v(s); (4.86)
where v is dened by equation (4.70).
The transformed problem may now be stated as: Choose v(s); ~uex(s); ti and Di; i =
1; : : : ;M; so as to minimize
~J =
Z N
0
v(s) (~x8(s)  ~gd(s))2 ds (4.87)
subject to the dynamics (4.74)-(4.86), the initial conditions (4.50) to (4.61) with t(0) = 0,
the parameter bounds: (4.31), (4.66) and (4.73), and subject to the constraints
gi = t(ki)  ti = 0; i = 1; : : : ;M; (4.88)
gn+1 = T   t(N) = 0: (4.89)
There is one feature in the transformed problem which prevents its direct implementation
in MISER3.3. In the transformed objective (4.87), we have the function gd(t(s)), where
t(s) is a state variable in the transformed problem. Recall from Chapter 1 that MISER3.3
assumes dierentiability of the objective integrand with respect to the state variables.
However, when choosing gd(t(s)) = gexp(t(s)) as dened in Section 4.2.4, this piecewise
linear function is not dierentiable with respect to t. Thus, we change the gexp from a
linear form to a quadratic form dened in equation (4.90) below and illustrated in Figure
4.2:
~gd = it(s)
2 + it(s) + i; t(s) 2 [ti 1(s); ti(s)]; i = 1; : : : ; 8; (4.90)
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i i i i
1  1:182857143 10 3 0.1656 5
2  9:178 10 4 0.128492 6.29878
3 1:828555556 10 3 -0.5306333333 45.8463
4  7:85 10 4 0.2534333333 -12.9587
5 4:003055556 10 4 -0.1732766667 25.4452
6  1:720357143 10 4 0.1014471429 -7.521657143
7 6:098125 10 4 -0.4927575 105.3772250
8  2:308472222 10 4 0.2133966667 -42.91515
Table 4.5: Parameter values of the gd function as quadratic form
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Figure 4.2: Experimental data in quadratic form
The parameter values dening this function are determined from a smooth piecewise
quadratic interpolation of the data in Table 4.1 and they are listed in Table 4.5. In sum-
mary, the transformed dynamic model consists of 13 state variables, ~xi(s); i = 1; : : : ; 12
and t(s), 2 control functions, ~uex(s) and v(s), and 2M system parameters, Di; i =
1; : : : ;M; and ti; i = 1; : : : ;M . These system parameters represent, respectively, the
volume of insulin injections and time points of these injections. In this model, the orig-
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inal time t 2 [0; 540] is transformed to a new time scale s 2 [0; N ]. For the numerical
results presented below, we assume up to M = 5 individual injections. We also assume
N = 20 and choose k1 = 0, k2 = 4, k3 = 8, k4 = 12 and k5 = 16 for the constraints
given in (4.88). Finally, the bounds on the control functions (equivalent to the parameter
bounds (4.66) and (4.73)) are
0 6 ~uex(s) 6 100; and 0 6 v(s) 6 540; s 2 [0; 20]: (4.91)
This version of the problem is in a a canonical form suitable for MISER3.3.
4.5 Numerical results
4.5.1 Case 1
The rst case that we tested is for a type 1 diabetic (Rm=0) with only one intermediate
acting insulin (NPH) injection at the beginning of the time horizon (t1 = 0) and with no
exercise. Here, we assume that the desired blood glucose function is gd(t) = gexp(t), where
gexp is in quadratic form as shown in Figure 4.2. This means that we are eectively trying
to emulate the blood glucose level of a healthy individual. This is a relatively simple
version of the problem with only one decision variable (D1), the dosage of insulin injected
at t1 = 0, where
0 6 D1 6 2:778 10 04: (4.92)
An optimal solution is readily obtained by MISER3.3. Figure 4.3 shows that the optimal
blood glucose trajectory follows the desired blood glucose prole only briey near the
beginning of the time horizon. The optimal value of insulin injection D1 is 2:28728 
10 04M which is equivalent to 32U . Clearly, one injection is not enough to achieve a
good glucose control over the entire time horizon and we will need to consider multiple
injections as well as exercise.
4.5.2 Case 2: Transformed composite model with exercise
This case also assumes a type 1 diabetic (Rm = 0) and we once again use gd(t) = gexp(t).
We consider two dierent types of insulin preparations, intermediate and short acting in
combination. Details of the bounds and initial guesses of ti; i = 1; : : : ; 5; are given in
Table 4.6. The bounds on the dosages are given in equation (4.93). Note that either
intermediate or slow acting insulin may be chosen for each injection and corresponding
values of ai; bi and si; i = 1; : : : ;M; must also be chosen. We indicate the values in table
4.7. In this case, we assume that the rst injection is an intermediate acting insulin while
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Figure 4.3: Comparison of two blood glucose trajectories: the solid curve is the optimal
trajectory for Case 1. The dashed curve is the desired trajectory
subsequent injections alternate between short and intermediate acting.
0 6 Di 6 2:0835 10 04; i = 1; : : : ; 5: (4.93)
A combination of dierent types of insulin injections as well as exercise yields better
results as shown in Figure 4.4. Figure 4.5 shows the optimal exercise level and Table 4.8
shows the optimal values of decision variablesDi and ti; i = 1; : : : ; 5. Note that eectively
just one injection is administered while exercise is used for most of the time horizon.
Decision variables ti Initial guess Lower bound Upper bound
t1 0 0 540
t2 108 0 540
t3 216 0 540
t4 324 0 540
t5 432 0 540
Table 4.6: Decision variable ti
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Insulin dosage Di
Parameter values
si ai bi
D1 2 1:5550756 106 294
D2 2 4:31965 105 102
D3 2 1:5550756 106 294
D4 2 4:31965 105 102
D5 2 1:5550756 106 294
Table 4.7: Insulin dosages and their corresponding parameter values of ai; bi and si; i =
1; : : : ; 5:
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Figure 4.4: Blood glucose trajectories for Case 2.
4.5.3 Case 3: Composite model without exercise
All details for this case are the same as those for Case 2, except that we assume no exercise
here, i.e. uex(t) = 0; t 2 [0; 540]:
As shown in Figure 4.6, the resulting blood glucose level still tracks the desired blood
glucose prole reasonably well. Note that the optimal solution involves a combination of
2 insulin types.
4.5.4 Case 4: Composite model for type 2 diabetes
In order to test the composite model for a type 2 diabetic case, we halve the original
insulin feedback rate (Rm = 0:5). Here exercise is once again considered and the same
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Figure 4.5: Optimal exercise level for Case 2.
types of insulin combinations as used in Cases 2 and 3 are assumed.
Clearly, Figure 4.7 shows that the resulting blood glucose level tracks the desired
blood glucose prole very closely. Figure 4.8 shows the corresponding optimal exercise
level. Also, the optimal values of insulin injections are listed in Table 4.10. Note that a
much lower dosage of insulin along with an earlier use of exercise is sucient to manage
good blood glucose control in this case.
Insulin injections Di Optimal values Injection times ti Optimal values
D1 1:70822 10 04M  24U t1 0
D2 0 t2 217.06
D3 0 t3 239.789
D4 0 t4 331.894
D5 0 t5 441.96
Table 4.8: Optimal values of decision variables Di and ti in Case 2
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Figure 4.6: Blood glucose levels resulting from optimization of the model without exercise
for Case 3
4.5.5 Case 5: Aiming for basal blood glucose level
In this case, we once again consider a type 1 diabetic (Rm = 0) and we adopt the objective
function
~J =
Z N
0
v(s) (~x8(s)  918)2 ds (4.94)
which simply penalizes any blood glucose deviation from the initial level. The problem is
to minimize (4.94) subject to the same dynamic model (4.38)-(4.61) as in previous cases.
Insulin injections Di Optimal values Injection times ti Optimal values
D1 1:16789 10 04M  16U t1 0
D2 5:08087 10 05M  7:3U t2 12.6863
D3 0 t3 203.28
D4 0 t4 327.639
D5 0 t5 439.112
Table 4.9: Optimal values of decision variables Di and ti in Case 3
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Figure 4.7: Blood glucose levels resulting for Case 4.
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Figure 4.8: Optimal exercise level for Case 4.
All details for this case are the same as those of Case 2, except for the objective function
and the assumed order of the insulin injections. We again assume that insulin injections
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Insulin injections Di Optimal values Injection times ti Optimal values
D1 0 t1 0
D2 1:77675 10 5M  2:5U t2 47.4842
D3 0 t3 273.071
D4 0 t4 372.92
D5 0 t5 437.78
Table 4.10: Optimal values of decision variables Di and ti in Case 4
have an alternating pattern, but this time starting with a short acting insulin.
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Figure 4.9: Blood glucose levels resulting from Case 5.
As can be seen from Figure 4.9, the optimal blood glucose level resulting in this case
remains very close to the initial blood glucose level (918 mg=l= 5.1 mmol=l) over the
entire time horizon. Figure 4.10 shows the optimal exercise level and Table 4.11 shows
the optimal values of the decision variablesDi and ti; i = 1; : : : ; 5. Due to the need to clear
a lot of glucose early on, multiple insulin injections early in the time horizon combined
with an early high level of exercise are required in this case.
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Figure 4.10: Optimal exercise level in Case 5.
4.6 Conclusions
We have developed a composite model that is capable of capturing the eects of exercise
and subcutaneous insulin injections. This model is based on the dynamical model of
the blood glucose regulatory system presented in [3]. Levels of exercise are described in
terms of the percentage of the maximum rate of oxygen consumption for an individual
and exercise is assumed to lead to higher levels of energy consumption and lower levels
of blood insulin. The appearance of blood insulin as a result of subcutaneous injections
is modelled according to a robust model proposed by Berger et al. [8].
Insulin injections Di Optimal values Injection times ti Optimal values
D1 1:31322 10 04M  18U t1 0
D2 6:27708 10 05M  9U t2 121.984
D3 0 t3 523.462
D4 0 t4 523.462
D5 0 t5 537.528
Table 4.11: Optimal values of decision variables Di and ti in Case 5
70 Insulin Injection and Exercise Scheduling for Diabetics
Based on this new dynamic model, we then formulate a combined optimal control
and optimal parameter selection problem with the objective of matching a desired blood
glucose prole as closely as possible. This problem involves variable switching times for
the control as well as multiple variable characteristic times in the dynamics. To make this
problem suitable for the optimal control software MISER3.3, a time scaling transformation
was invoked. We formulated a variety of cases to test the model. These included type 1
or 2 diabetic subjects, a single insulin injection at t = 0, multiple insulin injections with
or without exercise and two distinct desired blood glucose proles. While a single insulin
injection alone did not result in good blood glucose control, all other cases resulted in
eective control.
This work represents the rst application of a range of recent advances in the area
of computational optimal control to diabetes models and there is signicant scope for
future work in this regard. For example, just as we allowed for multiple insulin injection
times, it should be possible to incorporate multiple meals and also optimize the timing
of these meals. Another interesting challenge would be the incorporation of free fatty
acids (FFAs) into the model [49], since these also represent an important energy source
for the body. One should also investigate the possibility of incorporating other types of
treatments typical for type 2 diabetics.
CHAPTER 5
Conclusions
5.1 Main contributions of this thesis
This thesis has been concerned with the disease of diabetes, one of the major global health
problems threatening the wellbeing of humanity worldwide. A permanent cure for this
disease has been elusive until now, but it can be managed. This thesis proposes and
illustrates a general methodology for the analysis and control of the human blood glu-
cose regulatory system. In addition, it demonstrates that computational optimal control
methods can be readily used to determine open loop optimal controls for dynamic mod-
els of the blood glucose regulatory system, particularly in the context of diabetes. While
open loop controls do not take into account modelling errors and uncertainties in systems,
they still provide a useful benchmark for the performance of other more practical control
strategies. Using this approach, we can also test extreme scenarios on models and thus
identify their weaknesses.
In Chapter 1, the rst section is devoted to a brief discussion about diabetes; its
diagnosis, causes and consequent health problems that can result in the long term. It
describes the natural cycle of regulating the blood glucose level in the human body,
which is directed by the regulator hormones insulin and glucagon. It also describes in
detail a variety of factors that impact the blood glucose level in the human body. Then
various management strategies for diabetes are reviewed. From a mathematical point
of view, control methods of diabetes generally rely on dynamical models of the body's
blood glucose regulatory system. The remaining sections of Chapter 1 describe the basic
concepts of optimal control theory. This includes general formulations of optimal control
and optimal parameter selection problems, followed by a brief description of two solution
techniques used in the thesis, control parameterization and a time scaling transformation.
The powerful optimal control software MISER3.3 [25] is used throughout the thesis to
produce computational numerical results for a variety of scenarios related to this problem.
Chapter 2 gives a detailed review of mathematical models for the human blood glucose
regulatory system. This includes a range of algorithms to control blood glucose in diabet-
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ics. For each of these, their main features and respective contributions to the eld have
been outlined. However, very few of these algorithms are based directly on underlying
nonlinear models and thus they cannot take full advantage of the assumed nonlinearities.
The only work reviewed in Chapter 2 that uses computational optimal control methods
on the basis of a nonlinear model is [14]. Since its publication, signicant advances have
been made in the area of computational optimal control. In particular, we are now able
to deal with problems with variable decision points in the time horizon and these time
points may also appear in the objective function and in the dynamics.
The main original contributions of this thesis are given in Chapters 3 and 4, where we
rene, extend, test and optimize an existing model of intermediate complexity.
In Chapter 3, we adopt a comprehensive model of the blood glucose regulatory system
from Liu and Tang [31]. Based on their dynamic model, we formulate an optimal parame-
ter selection problem. The purpose of this formulation is to obtain more reasonable values
for many of the model parameters in the Liu and Tang model whose values are dicult to
determine directly. The objective in this formulation is to t the blood glucose trajectory
resulting from the model as closely as possible to real data [27]. Existing approaches gen-
erally just involve educated guesses of the values for these model constants. Furthermore,
these constants can vary signicantly between dierent subjects, and even over time for
the same subject, so there is clearly a need for simple and robust methods to determine
values for them. We investigated several dierent model matching objectives and found
that signicant improvements in matching the model to desired data was achieved in all
cases compared to the original results in Liu and Tang [31]. It is hard to judge the relative
quality of these results and the ultimate choice is best left to experts who are more fa-
miliar with the use of the model in relation to the real physical system. Nevertheless, we
have demonstrated that the proposed model matching strategy yields very good results
in this scenario. There is a wide variety of other biological systems for which the same
methodology should also prove useful (see for example [4], [6] and [42]). We also found
that the optimized model was more sensitive to changes in the insulin release rate (Rm)
proposed by Liu and Tang, but this is to be expected. Furthermore, we formulated an
open loop optimal control problem to determine optimal rates of insulin and glucagon
secretion and showed how it can be readily solved by MISER3.3. In contrast, the authors
in [31] considered this problem too dicult to solve.
In Chapter 4, we have developed a composite model that is also capable of captur-
ing the eects of exercise and subcutaneous insulin injections, based on the dynamical
model of the blood glucose regulatory system studied in Chapter 3. Levels of exercise
are described in terms of the percentage of the maximum rate of oxygen consumption for
an individual and exercise is assumed to lead to higher levels of energy consumption and
lower levels of blood insulin. The appearance of blood insulin as a result of subcutaneous
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injections is modelled according to a robust model proposed by Berger et al. [8].
Based on this new dynamic model, we then formulated a combined optimal control
and optimal parameter selection problem with the objective of matching a desired blood
glucose prole as closely as possible. This problem involves variable switching times
for the control as well as multiple variable characteristic times in the dynamics. To
make this problem suitable for the optimal control software MISER3.3, a time scaling
transformation was invoked. We formulated a variety of cases to test the model. These
included type 1 or type 2 diabetic subjects, a single insulin injection at t = 0, multiple
insulin injections with or without exercise and two distinct desired blood glucose proles.
While a single insulin injection alone did not result in good blood glucose control, all other
cases resulted in eective control. Thus, we have demonstrated that good blood glucose
can be achieved given moderate levels of treatment. The new model is a more integrated
and comprehensive model for the regulation of blood glucose levels in diabetics compared
to many existing models.
In summary, the work in Chapter 4 represents the rst application of a range of recent
advances in the area of computational optimal control to diabetes models and there are
many ways to extend both the model and the solution algorithms as detailed below.
5.2 Future research directions
We have reviewed a variety of mathematical models of the blood glucose regulatory system
and associated control algorithms for diabetics. A new methodology for matching such
models to actual data has been proposed and demonstrated to work well. Finally, we have
presented a new mathematical model by extending the Liu and Tang model [31] in two
ways. We discuss some additional possible improvements to the new composite model
below.
(i) In the Liu and Tang approach [31], to test the validity and credibility of their model,
they checked how the model ts experimental data reported in Korach-Andre et
al. [27]. We used the same experimental data in all our numerical results. This
data set consists of blood glucose measurements from a healthy individual taken
after meals. Future studies should perhaps consider dierent data sources or use
combined data from a larger sample set. It would also be interesting to test how
well the model t continues to match an individual over time.
(ii) In Chapter 4, just as we allow the new composite model to include multiple injection
times, it should be possible to incorporate multiple meal times (glucose sources) into
the model instead of only one meal. We may then also optimize the timing of these
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as another obvious treatment strategy. More accurate submodels of the digestive
tract may be needed in this case [37].
(iii) An interesting challenge would be the incorporation of free fatty acids (FFAs) into
the model, since these also represent an important energy source for the body. Roy
and Parker in [49] proposed a comprehensive model that takes into account the
important role of FFAs in the blood stream as a source of energy for the body. Its
dynamics consider important interactions between the levels of FFAs with exercise,
FFAs with glucose and FFAs with insulin concentration.
(iv) Finally, there are a variety of common medical treatments used for type 2 diabetics
before the need for insulin injections. Clearly, it would be of great benet to allow
for these treatments in our dynamic blood glucose regulatory model and consider
combined treatment regimes with a much wider variety of options. However, as
noted below, it is not always clear how these treatments can be adopted in the cur-
rent model or what extensions to the model are needed in order to do so. Progress
here will likely require input from practitioners more familiar with the underlying bi-
ological processes. We consider a variety of the most common non-insulin treatment
options below.
For ease of reference, we recall the Liu and Tang model from Chapter 2 at this point.
dx1
dt
=  (kp1;1 + kp1;2)x1 + w1; (5.1)
where
w1 =
Gm
1 + b1 exp a1(x8   C5) ; (5.2)
dx2
dt
=  (kp2;1 + kp2;2)x2 + w2; (5.3)
and
w2 =
Rm
1 + b2 exp a2(C1   x8) : (5.4)
dx3
dt
=  ks1;1x3(R01   x5)  ks1;2x3 +
kp1;1Vpx1
V
; (5.5)
dx4
dt
=  ks2;1x4(R02   x6)  ks2;2x4 +
kp2;1Vpx2
V
; (5.6)
dx5
dt
=  ks1;1x3(R01   x5)  kr1x5; (5.7)
dx6
dt
=  ks2;1x4(R02   x6)  kr2x6: (5.8)
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dx7
dt
= f4   f5; (5.9)
where
f4 =
k1x6
1 + k2x5
 V
gs
maxx8
kgsm + x8
; (5.10)
f5 = k3x5
V gpmaxx7
kgpm + x7
; (5.11)
and
dx8
dt
=  f4 + f5   f1   f2f3 +G; (5.12)
where
f1 = Ub

1  exp

  x8
C2

; (5.13)
f2 =
x8
C3
; (5.14)
f3 = U0 +
(Um   U0)x4
C4 + x

4
: (5.15)
(1) Metformin is usually the rst medication prescribed for type 2 diabetic patients.
It has a long history of usage in humans and was introduced in some countries as
early as the 1960s. Although some users experience gastrointestinal irritation
as a side eect, metformin is widely used and is considered to be very eective
in the early stages of type 2 diabetes. While the molecular mechanism of
metformin is not completely understood, its primary eect is to signicantly
reduce hepatic gluconeogenesis (production of glucose in the liver). This is
normally elevated in type 2 diabetic patients. Additional eects of metformin
include the increased insulin sensitity of cells (leading to increased uptake of
glucose) and a decreased absorption of glucose from the digestive system [7].
While reduced hepatic gluconeogenesis and increased insulin sensitivity may
be incorporated into our model by changing the model constants in equations
(5.11) and (5.13)- (5.15), respectively, the latter eect will likely require a more
complete dynamic model that includes the details of the digestive processes.
(2) Gliclazide is another common oral medication for type 2 diabetics. It essentially
stimulates the pancreas to release more insulin and works by binding itself
to certain receptors on the surface of pancreatic beta cells. Side eects of
taking gliclazide are rare, but patients must be careful not to over dose on this
medication as it can quickly lead to hypoglycemia [45]. Given its action, it
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should be possible to incorporate the eects of gliclazide by modifying one or
more of the constants in the insulin release rate in equation (5.4).
(3) Exenatide (sold under the trade names Byetta and Bydureon) is a more re-
cently introduced treatment option that is often prescribed when metformin is
no longer sucient to control the eects of type 2 diabetes. Unlike the oral
medications above, exenatide has to be injected subcutaneously. There is a
higher chance of side eects with the use of exenatide, particularly gastroin-
testinal irritation. However, in the absence of side eects, exenatide has several
benets for type 2 diabetics. It stimulates the pancreas to release more insulin
in response to consuming carbohydrates, it reduces the amount of glucagon
released from the pancreas after a meal (which in turn reduces hepatic gluco-
neogenesis), it slows down the passage of food from the stomach to the gut and
consequently gives an increased feeling of fullness. The latter eects are prob-
ably responsible for the weight loss that is widely observed for patients who
take exenatide. The mechanisms by which exenatide achieves these eects are
not well understood and it is consequently more dicult to incorporate these
into our existing model.
(4) A range of other medicines are also available for the treatment of type 2 di-
abetes. They work in manners similar to those mentioned above and thus
their possible incorporation into our existing model also follows along the lines
mentioned in points 1-3. Amongst the more popular ones, there is Rosiglita-
zone (sold under the brand name Avandia, it reduces the insulin resistance of
cells but its uptake has slowed signicantly after suspected side eects such
as heart failure became public), acarbose (which slows down the digestion and
absorption of certain carbohydrates in the intestines), and gliptins (also known
as DPP-4 inhibitors, they work by increasing insulin secretion and decreasing
glucagon secretion in the pancreas).
No doubt, many other medicines with similar eects will appear in the future and they
may, in many cases, also be incorporated into a dynamic blood glucose model.
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